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The 2013-2016 outbreak of Zaire ebolavirus (EBOV) in West Africa was 
unprecedented in scale and has sparked a great deal of interest into the pathogen. 
EBOV is the most pathogenic species in the family Filoviridae. Early symptoms are 
non-specific and flu-like, but these rapidly dissolve into systemic issues, frequently 
resulting in death. Fatal infections are associated with uncontrolled inflammation, 
while survivors have an initial robust antiviral response followed by an effective 
antigen-specific response. However, there are a myriad of other factors influencing 
patient outcome, including viral load and co-infections. The elucidation of these 
factors could have major therapeutic implications.  
 
RNA-sequencing via Illumina and Nanopore platforms was performed on the 
diagnostic samples of patients during the outbreak in order to explore many facets 
of EBOV biology. The nature of these samples allowed investigation into the 
determinants of patient outcome following Ebola virus disease (EVD). Blood was 
taken from acutely ill individuals at a time when it was not known whether they 
would survive and clear the infection or succumb to it. These data allowed 
investigation into viral genome variation and the potential role of viral quasispecies 
in patient outcome, as well as the study of defective interfering particles in vitro – a 
potential mechanism for viral persistence. The immune response to the pathogen 
was assessed via the comparison of gene expression and predicted immune cell 
profiles. Bioinformatic techniques were also employed to search these diagnostic 
samples for other microorganism such as bacterial and fungal species.  
 
Here we demonstrate that higher viral load and malaria co-infection are correlated 
with poor patient outcome. There are a number of genes that are differentially 
expressed according to patient outcome – e.g. those associated with blood clotting 
and complement regulation. These data allowed the employment of a linear 
discriminant analysis which, following qRT-PCR of EBOV and three host genes, was 
able to predict patient outcome with exceptional accuracy. Thus suggesting that the 
response of survivors differs to that of fatalities during EBOV infection. The 
identification of potential microorganisms in the blood of EVD patients is suggestive 
of gut translocation of bacteria. This points towards the potential use of antibacterial 
agents in conjunction with treatment for EVD during outbreak settings. Potential 
defective interfering particles were readily detected upon sequencing of infected 
THP-1 cells, however, were not often found in clinical samples taken from EVD 
patients. These samples included those from immune-privileged niches, i.e. semen, 
and may suggest that Dis are not responsible for the persistence of EBOV following 
acute infection.  
 
This thesis highlights the fact that animal studies, cell culture and the analysis of 
clinical samples should be considered in tandem in order to effectively study all 
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Chapter 1: Introduction 
 
1.1 Project overview 
 
This project was formed in response to the beginning of the largest Ebola outbreak in 
history, first confirmed in West Africa in 2014. Although vast and significant 
improvements have been made both in terms of vaccines to Zaire ebolavirus (EBOV) 
and effective treatments in response to that outbreak, the zoonotic nature of this virus 
means that outbreaks are likely to occur in the future. These outbreaks will likely occur 
in settings where the delivery of vaccines and drugs pose challenges. Therefore, the 
further understanding of disease progression and pathogenesis could provide valuable 
information to healthcare workers, either for personalised treatments or the triage of 
patients. In order to explore this, three aspects were investigated: (1) The virus itself, 
(2) the host immune response to Ebola virus disease (EVD) and (3) the potential role of 
co-infections in patient outcome. Understanding the differences between acute 
sufferers of EVD and their fatal counterparts in terms of immune response could also 
potentially lead to the development of a prognostic tool. For this to be effective it 
would have to be able to be performed in relatively low-resource laboratories, which 
limited the potential methodologies that could be implemented.   
 
Currently, a measurement of EBOV Ct (following quantitative (q)RT-PCR of blood) is 
used as a proxy for viral load and this gives some indication as to the prognosis of the 
patient. However, there are many cases when this value is intermediate and provides 
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no information concerning the patient’s likely outcome. Once developed, such a 
prognostic tool may be implemented in other outbreaks, where viral load is not such 
an accurate indicator of outcome.  
 
1.2 Ebola virus  
 
Ebolavirus is a genus of the family Filoviridae and order Mononegavirales. Within this 
genus exists six known species: Bundibugyo ebolavirus (BDBV), Reston ebolavirus 
(RESTV), Taï Forest ebolavirus (TAFV), Sudan ebolavirus (SUDV), Bombali virus (BOMV) 
and Zaire ebolavirus (EBOV), which will be the focus of this thesis. Many of these 
species are capable of causing EVD, with varying mortality rates. EBOV causes the most 
frequent outbreaks and those capable of causing the highest case fatality rates - up to 
90% (Formenty et al., 2003; Weyer et al., 2015). EBOV is a zoonotic virus and able to 
infect not only in non-human primates (NHPs) but also other mammals with bats being 
a likely reservoir (Leroy et al., 2005; Pourrut et al., 2009; Hayman et al., 2010; 
Goldstein et al., 2018). This zoonotic nature allows periodic outbreaks to occur, with 
the bushmeat of bats being the source of the 2013-2016 outbreak (Mari Saez et al., 
2015). Since their discovery, the zoonotic potential of filoviruses has been understood. 
Marburg virus (MARV) was confirmed to be present in Rousettus aegypticus bats, 
implicating them early on as being a potential reservoir. Since then, Ebola viruses have 
been confirmed to be present in bats and rodents as well as the bodies of chimpanzees 





Ebolaviruses are highly transmissible, principally by direct contact with contaminated 
body fluids and fomites (Bausch et al., 2007), though aerosol transmission has been 
achieved in laboratory conditions (Johnson et al., 1995; Zumbrun et al., 2012; Nfon et 
al., 2013). The 2013-2016 outbreak was sparked by one zoonotic jump, with all 
subsequent transmissions being due to human-human interactions. This was partially 
facilitated by the fact that individuals continue to secrete the virus after death, and a 
number of traditional burial practises include direct contact with the body. One aspect 
of the response to outbreaks of EVD has been the dissemination of information 
concerning safe funeral practises (Tiffany et al., 2017). The 2013-2016 outbreak also 
saw the first confirmed case of sexual transmission of the virus (Diallo et al., 2016).   
 
Outbreaks in human populations tend to start following an initial spillover event from 
an infected reservoir to an alternate species, with numerous epizootic outbreaks 
having occurred in NHPs in the Republic of Congo and Gabon (Leroy et al., 2004). 
These spillover events can be due to human activity – e.g. hunting or poaching or 
NHPs, with infected NHPs believed to be responsible for sparking several EVD 
outbreaks (Formenty, Boesch, et al., 1999; Formenty, Hatz, et al., 1999; Reed et al., 
2014). This interplay between suspected reservoirs, vulnerable NHPs and human 
populations is not well understood when it comes to EVD.   
 
1.2.2 Outbreaks 
Since its first discovery in 1976, there have been a number of outbreaks involving 
ebolavirus infections, as summarised in Table 1.1. In order to confirm such outbreaks, 
access to adequate testing facilities is essential, as confirming EVD clinically poses 
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many challenges due to the non-specific nature of the exhibited symptoms. This was 
shown once again in the 2013-2016 outbreak in West Africa, where the initial cases 
were assumed to be malaria infections (Baize et al., 2014).   
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Table 1.1: Summary of confirmed EVD outbreaks throughout history. The location and 
date of outbreak is shown along with the absolute number of cases, deaths and case 
fatality rate (CFR). * denotes estimated CFR due to ongoing outbreak. Data sourced 
from Centers for Disease Control and Prevention, accessed 01/08/19 (CDC, 2019a). 
Date Country Human cases Human deaths 
(CFR) 
Ebola virus (EBOV) 
Aug 2018 – present Democratic Republic of 
the Congo 
Limited cases: Uganda 
3 373 1 986 (59%*) 
May – July 2018 Democratic Republic of 
the Congo 
54 33 (61%) 
Aug – Nov 2014 Democratic Republic of 
the Congo 
66 49 (74%) 
Dec 2013 – Jan 
2016 
Liberia, Sierra Leone, 
Guinea 
Limited cases: Nigeria, 
Mali, USA, Senegal, 
Spain, UK, Italy 
28 646 11 323 (70-71%) 
Dec 2008 – Feb 
2009 
Democratic Republic of 
the Congo 
32 14 (45%) 
Aug – Nov 2007 Democratic Republic of 
the Congo 
264 187 (71%) 
2005 Republic of the Congo 12 10 (83%) 
Nov – Dec 2003 Republic of the Congo 35 29 (83%) 
Dec 2002 – Apr 
2003 
Republic of the Congo 143 128 (90%) 
Oct 2001 – Jul 2002 Gabon, Republic of 
Congo 
124 97 (78%) 
July 1996 – Mar 
1997 
Gabon 60 45 (75%) 
Jan – Apr 1996 Gabon 31 21 (68%) 
May – July 1995 Zaire 315 254 (81%) 
Dec 1994 – Feb 
1995 
Gabon 52 32 (60%) 




1.2.3 2013-2016 Outbreak of EVD in West Africa 
Periodic outbreaks of EVD occurred from its discovery in 1976 until the re-emergence 
of the virus in West Africa in 2013.  This outbreak was unprecedented in scale and has 
elucidated previously unappreciated aspects of EBOV biology, such as persistence in 
semen and ocular fluid (Deen et al., 2015; Varkey et al., 2015). The first cases of EVD 
were reported in March 2014 in the forested region of Guinea (Baize et al., 2014). 
Using phylogenetic analysis, the first cases of the outbreak were traced back to 
December 2013, which was supported by epidemiological evidence. These data 
suggested that EBOV-Makona, titled as such after a river running through Sierra Leone 
and subsequently along the borders of Guinea and Liberia (Kuhn et al., 2014), was 
exposed to humans via the interaction between a young boy and a dead bat (Simon-
Lorière et al., 2015). Throughout this outbreak over 28,000 people were infected and 
11,300 succumbed to the effects of EVD (Table 1.1). This outbreak mainly affected 
three countries: Guinea, Sierra Leone and Liberia, with sporadic but isolated cases 
occurring in surrounding countries. EBOV-Makona has been shown to have different 
growth kinetics when compared to other strains according to experimentally infected 
NHPs and mice, where delayed onset of disease and reduced lethality were observed 




Figure 1.1: Map of West Africa during the 2013-2016 Ebola outbreak. Shown here are 
Guinea, Liberia and Sierra Leone, the three most prominently affected countries of the 
outbreak. Districts are coloured according to number of EVD cases reported between 
March 2014 and March 2016. The area considered to be the epicentre of the outbreak 
is depicted by the red circle. The map of Ebola cases in West Africa was adapted from 




The epicentre of this outbreak was critical in understanding its subsequent spread and 
scale. It began in a remote part of Guinea, close to the borders of Sierra Leone and 
Liberia (Figure 1.1). These borders are porous, and much is shared across them 
including entire families. This made isolation of hot zones and controlling the outbreak 
challenging. Interestingly, the CFR was not constant between these three majorly 
affected countries (Figure 1.2). This thesis focussed on samples from Guinea, the 
country that experienced the highest case fatality rate, and therefore potentially the 
most extreme conditions both for the virus and host. Guinea is a developing country 
with limited infrastructure. Therefore, few palliative care measures were implemented 





Figure 1.2: Tracking the case fatality rate across the outbreak in Guinea, Liberia and 
Sierra Leone. Data collected from the Centers for Disease Control and Prevention, 
accessed 07/05/19 (CDC, 2019b). Graph shows the percentage of cumulative suspected 
cases that have resulted in death. These are suspected and lab-confirmed cases 

































































































1.3.1 Virion structure 
Ebolavirus virions are filamentous in their morphology, varying in length from 800 nm 
to 1 m, but with a relatively uniform diameter of 60 nm (Baskerville et al., 1985; Noda 
et al., 2002). The main structural proteins of EBOV are the membrane protein (VP40) 
and the glycoprotein (GP) (Figure 1.3A). There are also several non-structural proteins 
that aid in viral replication and viral transcription: i.e. VP35 and VP30, while VP24 plays 
a key role in viral packaging and interacting with host restriction factors. The viral 
polymerase (L) is critical in viral replication and transcription and the nucleoprotein 
(NP) encapsulates viral RNA to form the ribonucleoprotein complex (RNP) (Muhlberger 
et al., 1999). This packaging facilitates viral replication and also protects the viral RNA 





Figure 1.3: Schematic depictions of Ebolavirus and its genome. Morphological 
representation of Ebola virus shows its filamentous nature, hence the genus name 
Filovirus (A). The outer membrane consists of interlinking matrix proteins (VP40), in 
which the glycoproteins (GP) are embedded, covering the entire surface area of the 
virion. Viral protein (VP)24 is associated with the membrane, being partially within the 
nucleoprotein (NP). NP is found within the capsid, along with the viral RNA to form the 
ribonucleoprotein (RNP) complex. Also present are the polymerase (L), replication 
activator (VP30) and transcriptional activator (VP35). Negative sense RNA genome of 
Ebola virus organised 3’ to 5’ (B). Like all ebolaviruses this is an unsegmented negative 
sense RNA genome. Transcription occurs sequentially from 3’ to 5’ ends. During 
replication, the entire genome is transcribed to produce an anti-genome, which acts as 
a template for the generation of further viral genomes. GP consists of GP1 and GP1, 
cleaved by the host protein furin. The RNA editing site allowing for the different GP 
products is also highlighted.   
  
Matrix protein (VP40) 
Polymerase (L) 
Viral protein 24 (VP24) 
Viral protein 30 (VP30) 
Nucleoprotein (NP) 




NP VP35 VP40 sGP 
GP 
GP1 GP2 
Furin cleavage  
ssGP 
RNA editing site 
VP30 VP24 L OH 3’ 5’ 
Negative sense RNA genome 
 21 
1.3.2 Genome structure and organisation 
The genome of EBOV is 18.9Kb - negative sense RNA genome encoding seven genes 
(Figure 1.3B) (Brauburger et al., 2014). Transcription is sequential from the 3’ end, with 
all but one gene encoding for a single protein: NP, VP30, VP35, GP, VP40, VP24 and L. 
As well as full-length GP, this gene produces three transcriptional products: secretory 
(s)GP, small (s)sGP and delta-peptide (Mehedi et al., 2011; He et al., 2017; Wahl-
Jensen et al., 2005). Flanking each EBOV gene exists an open reading frame (ORF) 
consisting of untranslated sequences as well as highly conserved transcription start 
and stop signals.  
 
1.2.4 Viral proteins 
This genome encodes seven structural proteins: NP, VP35, VP40, GP, VP30, VP24 and L 
as well as two non-structural proteins: sGP and ssGP (Elliott 1985, Feldman 1993).  
 
1.2.4.1 Nucleoproteins  
The major nucleoprotein, NP, and minor nucleoprotein, VP30, bind to viral RNA. NP 
binds to viral RNA in order to form the RNP, encapsulating the RNA, shielding it from 
degradation by cellular processes and facilitating viral transcription (Noda et al., 2010). 
NP is essential for viral replication and, as such, many regions of this gene are highly 
conserved among the order mononegavirales (Muhlburger et al., 1999; Muhlburger 
2007; Sanchez et al., 1992).  
 
The role of VP30 is in the activation of transcription, which again is imperative for the 
virus lifecycle (Martinez et al., 2008; Muhlberger et al., 1999; Biedenkopf et al., 2016). 
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The activity of VP30 is enhanced by a secondary RNA structure which facilitates the 
production of viral transcripts via polymerase activity (Biedenkopf et al., 2016).  
 
1.2.4.2 Viral protein 35 (VP35) 
VP35 is a phosphoprotein with two main functions: acting as a co-factor for the viral 
polymerase L and as a facilitator of immune evasion. This is achieved by interfering 
with the host’s establishment of an antiviral state. VP35 interrupts signalling pathways 
such as RIG-I and interferon regulatory factor (IRF-)3 (Hartman et al., 2008; Basler et 
al., 2003; Ilinykh et al., 2015).  
 
1.2.4.3 Glycoprotein (GP) 
The major product of the GP gene is a soluble non-structural glycoprotein – sGP – but 
structural proteins GP1 and GP2 can be produced following RNA editing. GP2 enables 
entry into host cells by acting as a fusion protein (Noda et al., 2002; Carette et al., 
2011). GP1 and GP2 form a trimer in order to mediate membrane fusion (Lee et al., 
2008). The cellular receptors for EBOV are not fully understood, but DC-SIGN, LSECtin, 
β-integrins and Tyro3 receptors have been implicated (Takada et al., 2004; Marzi et al., 
2004; Zhao et al., 2016., Schornberg et al., 2009; Hunt et al., 2011). However, these 
factors are not essential for EBOV entry. This entry occurs via endocytosis and to 
permit release into the cytoplasm, GP must be catalysed by Cathepsin B/L, which trims 
GP1 and removes the mucin domain, allowing access to other binding sites for 
additional receptors in the endosome (Aleksandrowicz et al., 2011). GP then binds 
NCP1, enabled by furin (Carette et al., 2011). NCP1 is involved in cholesterol trafficking 




The primary product of the GP gene is a non-structural secretory glycoprotein – sGP. 
The N-terminal regions of sGP, ssGP and GP1 are identical though the C-terminals are 
different. Therefore, it has been hypothesised that sGP may act as a protective decoy, 
delaying the success of antibodies produced in response to the virus (Lee et al., 2008; 
Iwasa et al., 2011). sGP has also been implicated in the activation of endothelial cells 
and therefore promoting vascular leakage via the weakening of cell junctions (Wahl-
Jensen et al., 2005). This is readily observed in patients with EVD. A truncated version 
of sGP, ssGP, can be formed, though its function is not well understood (Mehedi et al., 
2011). 
 
1.2.4.4 Matrix protein VP40 
VP40 oligomerises in order to form stable structures, particularly in areas known as 
lipid rafts, at the plasma membrane (Hoenen et al., 2010). These areas comprise of 
high cholesterol and sphingolipid concentration, which, following budding, are 
involved in the formation of the viral envelope. VP40 forms a complex with the RNP in 
these areas to initiate virion self-assembly, which precedes viral budding through the 
membrane (Noda et al., 2002; Hoenen et al., 2010). VP40 also binds to the C-terminal 
of GP to act as an anchor while the mucin domain penetrates the surrounding 
envelope.  
 
1.2.4.5 Viral protein 24 (VP24) 
The roles of VP24 are numerous and multi-faceted. VP24 acts as a co-factor in virion 
assembly by associating with the RNP and potentially aiding in the packaging of NP 
(Watt et al., 2014). In the absence of VP24, virion packaging efficacy is interrupted, 
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though the viral lifecycle is unaffected (Zhang et al., 2012; Watt et al., 2014). The other 
main role of VP24 is that of an interferon antagonist (Zhang et al., 2012). The binding 
of VP24 to karyopherin-α halts the translocation of STAT1/STAT2, which spark the 
transcription of IFN response genes. In experimentally infected guinea pigs, mutations 
in the VP24 region were associated with an increase in pathogenicity as the virus 
adapted to the guinea pig host (Dowall et al., 2014).   
 
1.2.4.6 Viral polymerase (L) 
The RNA dependent RNA polymerase (RdRp) associates with viral RNA in order to 
transcribe messenger (m)RNA and promote replication. The polymerase binds to the 3’ 
domain in a specific region in the UTR (Muhlberger et al., 2007). The concentration of 
NP will dictate whether the polymerase will produce full-length RNA anti-genomes or 
mRNA for viral genes by association with VP30 (Noda et al., 2011). This gene is highly 
conserved across the Ebolavirus genus due to its essential role in the replication and 
spread of the virus (Oany et al., 2015).  
 
1.2.5 Viral replication 
EBOV replication occurs within inclusion bodies formed between NP and host proteins 
(Hoenen et al., 2012). Once formed, this virion can enter endosomes by 
micropinocytosis or clathrin-mediated endocytosis. Both processes involve the 
formation of invaginations in the plasma membrane that engulf the endosome, in 
which GP plays a role. NCP1 is able to initiate the fusion of the viral membrane to the 
vesicle membrane, thus releasing the RNP into the cytoplasm. The critical role of GP in 
viral entry has been demonstrated via the introduction of mutations into GP in vitro, 
where these changes had the ability to restrict viral entry (Martinez et al., 2013).  
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Following the release of the RNP, sequential transcription of viral mRNAs occurs, along 
with genome replication. This process begins with the synthesis of a complementary 
antigenomic RNA, regulated by L, which acts as a template for future replication. The 
trigger for replication is thought to be initiated by the expression of NP, once 
encapsidation of the antigenomic template has occurred. Upon the generation of 
sufficient viral material within the inclusion bodies, these RNA genomes are 
encapsidated and virions formed. Here, RNP complexes they migrate to VP40 
assemblies at the plasma membrane (Nanbo et al., 2013).  
 
1.2.6 The formation of viral quasispecies 
The error-prone nature of the viral polymerase, along with potential recombination 
events, leads to the generation of viral quasispecies. These describe the mutant 
spectra of closely related viral genomes that exist in one infection, constantly 
undergoing genetic variation and competition with other variants (Domingo et al., 
2012). These viral populations exist even in a single cell as well as at the level of an 
infected organism (Del Portillo et al., 2011; McWilliam Leitch and McLauchlan, 2013; 
Gire et al., 2014). This allows viral genomes to shift and gain or lose fitness throughout 
the course of an infection, which has been demonstrated to be critical in viral 
adaptation (Domingo and Holland, 1997). The association between viral fitness, 
disease progression and response to antiviral therapy was demonstrated in hepatitis C 




Figure 1.4: Schematic diagram depicting the selection for certain mutations in the 
evolution of viral quasispecies. The error-prone nature of the viral polymerase allows 
the introduction for point mutations. The initial viral population is subject to change 
over time. Those mutations that provide a fitness benefit are maintained within the 
viral quasispecies, whilst those that are detrimental are selected against. Therefore, 
over time an increase in fitness is expected, along with these accumulated mutations. 
Here, the viral genome is depicted as a horizontal black line, while mutations are 

















1.4 Persistent filovirus infections 
 
Due to the sheer number of infected individuals, the outbreak in West Africa 
highlighted a number of aspects of EBOV that were previously unknown or poorly 
understood. One example of this is the persistence of the virus for long periods of time 
within an infected host, often not accompanied by physiological symptoms (Leroy et 
al., 2001). This persistence, especially in body compartments considered to be 
immune-privileged niches such as the testes, are particularly problematic as they raise 
the potential for further human-human transmissions via sexual contact, as shown in 
EBOV in 2015 (Christie et al., 2015). The first case of sexual transmissions of a filovirus 
was observed in an outbreak of Marburg virus (MARV) in 1968 (Martini and Schmidt, 
1968). Additionally, such persistence could be the cause of substantial sequalae 
observed in survivors, among whom there are a plethora of long-term health 
consequences associated with EVD (Clark et al., 2012; Quaglio et al., 2019; Ficenec et 
al., 2019; Kelly et al., 2019). This includes damage to reproductive health, 
psychological effects and injury to the sight of convalescent patients.  
 
1.4.1 Defective interfering (DI) particles  
In most RNA viruses, truncated forms of the viral genome are produced during 
replication during growth in vitro (Calain et al., 1999; Rima and Duprex, 2005). These 
defective genomes have been suggested as antiviral in nature, due to their ability to 
interfere with viral transcription and/or packaging (Marriott and Dimmock, 2010). 
However, the understanding of the role of DIs in vivo is less well understood (Barrett et 
al., 1986). Broadly speaking, DIs fall into three categories: deletion, copy-back and 
hairpin DIs (Dimmock and Easton, 2014). This self-imposed system has been suggested 
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as the mechanism by which EBOV, and other RNA viruses, maintain persistent 
infections. Such infections appear to lack visible symptoms and represent infections in 
which the environment has become immune-tolerant to the pathogen. Viral 
quiescence describes a latent form of the virus, which is able to sequester and remain 
in the infected host for extended periods of time, as demonstrated in many viruses 
including HSV, CMV and Rift Valley fever virus (Jaimieson et al., 1995; van Vuren et al., 
2019; Russell and Tscharke, 2016; Poole and Sinclair, 2015).  
 




The high CFR observed in outbreaks of EVD is achieved by “immune paralysis” – a total 
overwhelming of the immune system due to uncontrolled viral replication. Analysis of 
patients from the 2013-2016 EBOV outbreak in West Africa including four patients who 
received intensive treatment at Emory University Hospital (GA, USA) indicated that 
infected individuals had a robust immune response during the acute phase of EVD 
(McElroy et al., 2015). This, and findings from previous outbreaks, challenges previous 
in vitro studies that suggested EBOV was able to effectively suppress the immune 
system (McElroy et al., 2015). In these studies, EBOV appeared to diminish the activity 
of T lymphocytes, dendritic cells (DCs) and macrophages. These cell types are targeted 
by EBOV early in infection (Geisbert, et al., 2003).  
 
1.5.1 Inflammatory response 
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Certainly, in NHP models of fatal EBOV infection, an extreme aberrant immunological 
status and anti-inflammatory response was shown to contribute to the development 
of fatal haemorrhagic fever (Ebihara et al., 2011) and this has also been observed 
together with lymphocyte apoptosis and other indicators of immunopathology in fatal 
human infections with EVD (Wauquier et al., 2010). Analysis of samples from EBOV-
infected patients treated in Guinea also revealed an immune component influenced 
survival (McElroy et al., 2015; Ruibal et al., 2016). The study of patient samples taken 
from previous outbreaks suggests that host responses may delineate survival and fatal 
outcomes and potential biomarkers indicative of these outcomes can be identified. In 
the 2000–2001 Sudan-associated Ebola (SUDV) outbreak in Uganda, the case fatality 
rate for paediatric patients was lower than for adults (Mupere et al., 2001). Data 
indicated that paediatric patients who survived had differential abundance of certain 
serum proteins from paediatric patients who died and that, in contrast, adults had 
similar levels of these same molecules (McElroy et al., 2014b).  
 
EBOV initially undergoes massive replication in immune cells: macrophages and 
dendritic cells (DCs) and then spreads to many other cell types, infecting all vital 
organs (Zampieri et al., 2007; Falasca et al., 2015). This high viraemia is associated with 
massive production of pro-inflammatory cytokines and chemokines, lymphocyte 
apoptosis and the destruction of local tissues. This damage leads to increased 
endothelial permeability and therefore to multiorgan failure and systemic clotting 
disorders (Zampieri et al., 2007; Liu et al., 2017). These deleterious effects are 
heightened in fatal compared to non-fatal or indeed asymptomatic infections (Leroy et 
al., 2001). These latter cases are thought to be relatively rare, but are obviously 
challenging to identify.  
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The hypersecretion of cytokines are most notable in the pro-inflammatory group, 
including interleukin (IL)-1b, IL-1RA, IL-6, IL-8 and IL-15, along with a number of 
chemokines and growth factors such as MIP-1a, MIP-1b and IP-10 (Wauquier et al., 
2010). Many of these cytokines are also found to be readily produced in non-human 
primates (NHPs) after challenge with EBOV (Geisbert et al., 2003; Ebihara et al., 2011). 
The resulting cytokine storm is a key part of the immunopathology caused by EBOV 
infection.  
 
During EBOV infection, T-lymphocytes in the blood are seen to be depleted, along with 
natural killer cells (Reed et al., 2004; Wong et al., 2014). The individuals who fail to 
produce a robust immune response are more likely to suffer a fatal infection. The 
response to EBOV infection is a careful balance which must be maintained. A sufficient 
immune response is required, but an uncontrolled response is what causes much of 
the immunopathology associated with the virus.  
 
Due to the international contribution involved in the 2013-2016 outbreak, analysis of 
four individuals undergoing treatment for EVD in the USA provided an opportunity to 
study acute EVD in the absence of outbreak conditions. Here, patients were observed 
to exhibit a robust proinflammatory response, which supports much of what has been 
concluded following in vivo experiments with NHPs. However, this challenged the 
potential immune-dampening activities of the virus itself. 
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1.6 Known determinants of patient outcome 
 
The processes that lead either to survival or a fatal infection are not well known 
although viral load is known to be a key determinant. This is especially relevant at 
extremes, where patients with very high viral loads are more likely to suffer a poor 
prognosis. Factors influencing patient outcome in EVD cases include access to palliative 
care, anti-viral treatment, age and the presence of co-morbidities.  
 
1.6.1 Palliative care  
Supportive care has been suggested to be one of the key factors that helped reduce 
the average fatality rate across the 2013-2016 EBOV outbreak, which initially sat at 
over 70% (Lamontagne et al., 2018). The scale of this outbreak meant that the 
provision of this palliative care was even more challenging than those previous, being 
impossible in some areas at the peak of the outbreak due to limitations of 
infrastructure and resources (Fowler et al., 2014). Oral hydration is critical in infections 
that cause similar symptoms to EVD - i.e. diarrhoea, volume depletion and shock or 
organ hypoperfusion – such as cholera. In such cases the fatality rate can be greatly 
reduced upon rehydration of patients (Mahalanabis et al., 1973).  
 
1.6.2 Age 
In the 2000-2001 outbreak of SUDV in Uganda, the mortality rate was seen to be 
greatly affected by age, with paediatric patients seen to experience lower fatality rates 
(McElroy et al., 2014a). Following analysis of serum samples from this outbreak, the 
surviving paediatric patients were seen to have elevated levels of certain cytokines and 
chemokines, which may have played a significant role in their survival. The same 
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difference was not observed in adults, which suggests that EVD patients of differing 
ages could require different treatments. Individuals aged 60-64 were at highest risk 
(McElroy et al., 2014a). Conversely, in the 2013-2016 outbreak, children under five 
were seen to be at higher risk of death (Cherif et al., 2017).  
 
1.6.3 Coinfections 
A large proportion of the patients presenting to the Ebola treatment centre (ETC) 
tested positive not only for EBOV but also Plasmodium falciparum, indicative of an 
active malaria infection. Malaria as a co-infection has been implicated in the outcome 
of EVD, with groups finding that it can have beneficial (Rosenke et al., 2016) or 
deleterious effects (Waxman et al., 2017).  Malaria has long been associated with co-
morbidity and as a complicating factor in a number of viral infections, from HIV to EBV 
and human parvovirus B19 (Rénia and Potter, 2006; Toan et al., 2013; Waxman et al., 
2017). Guinea experiences high levels of malaria transmission (>1 case per 1000 
population), with P. falciparum being responsible for 100% of cases in 2013 (WHO, 
2014). 
 
Other coinfections have the potential to aid the immune response in battling EVD. The 
presence of GB virus C (GBV-C) (formally known as hepatitis G virus) was examined in 
49 patients positive for EBOV from Sierra Leone, where both survival and GBV-C status 
were found to be associated with age (Lauck et al., 2014). There have been several 
case reports of Gram-negative septicaemia in patients with EVD (Kreuels et al., 2014), 
although very little data exist regarding the frequency of this septicaemia. However, 
the incidence of bacteraemia appeared to be low upon clinic admittance (Lamb et al., 
2015). Despite this, assessing the presence of bacterial infection of the blood from 
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large numbers of patients infected with high-consequence infections is complicated, 
particularly under field conditions of high containment, where the primary need is to 
provide an accurate diagnosis of EBOV. Therefore, bacterial coinfections could 
frequently be missed.  
 
1.7 RNA sequencing  
 
Transcriptomics, achieved via next generation sequencing (NGS), have been 
revolutionary in biomedical research. This allows for the abundance of transcripts to 
be calculated, with a greater abundance suggesting an enhanced gene expression. In 
RNA sequencing (RNAseq), transcripts are quantified and the relative abundance of 
transcripts can be elucidated. This allows the activity of genes and their downstream 
pathways to be investigated. Due to the high containment nature of EBOV, 
transcriptomics provides an avenue to allow the study of the host response to the 
virus, as well as sequence changes in the virus itself. NGS is particularly useful in 
studying the dynamics of viral quasispecies.   
 
1.7.2 Illumina and Nanopore sequencing 
Illumina sequencing enables the generation of millions of accurate reads from an initial 
sample. Reads are roughly 150 bp in length and many known pipelines exist for the 
study of Illumina data, due to its established nature.   
 
Like Pac-Bio, Nanopore sequencing generates reads of substantial length, up to many 
thousands of base pairs. Here, RNA binds to pores on a membrane, which passes the 
nucleic acid through the pore (Figure 1.5). This leads to a change in voltage that is 
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measured as a “squiggle”, giving a read-out of the predicted base at that position. The 
major advantage of Nanopore sequencing is that it can be performed rapidly and with 
limited training, while the error rates produced by this platform are much higher than 
that of Illumina.  
 
These two techniques are both very useful in the study of viral infections, each with 





Figure 1.5: Schematic diagram of a Nanopore sequencing DNA. Here, DNA has been 
accepted into the nanopore (grey), which is controlled by the unwinding enzyme 
(brown). The nanopore is embedded in a lipid bilayer and an electric field applied. This 
electric field is capable of controlling the direction of the DNA through polymerase 
activity. DNA sequence information is recorded in the form of a “squiggle” – i.e. 
changes in the ionic current running through the pore. Adapted from Schneider and 













1.8 Research objectives 
 
The aim of this project is to use transcriptome data from acutely infected and 
convalescent patients to identify factors that are associated with patients that survived 
or succumbed to EVD. This is likely to be a complex analysis and a mixture of viral, host 
and external factors. The role of the viral sequence itself as well as the potential role of 
co-infections have not been well investigated previously, while the host response is 
known to readily affect patient outcome. The 2013-2016 outbreak in West Africa and 
the involvement of the EMLab has provided a unique opportunity to study this virus 





Chapter 2: Materials and methods 
 
All virus preparation and viral infections were performed by collaborators at Public 
Health England (PHE), Porton Down under CL4 conditions, where I assisted in the 
downstream processing of samples following viral inactivation. The Illumina 
sequencing was performed by a team at the Centre of Genomic Research (CGR) at the 
University of Liverpool and Dr. David Matthews at the University of Bristol.  
 
2.1 Patient samples 
 
2.1.1 Ethical approval 
Ethical approval for use of residual diagnostic RNA extracts from blood/other bodily 
fluids from individuals suffering from acute Ebola virus disease was obtained from the 
National Committee of Ethics in Medical Research of Guinea (permit number 
11/CNERS/14). Informed consent was not obtained from patients due to the nature of 
the sample collection as part of the public health response to the 2013-2016 outbreak 
of Ebola.    
 
2.1.2 Human samples 
All samples in this study were provided by the Bernhard-Nocht Institute for Tropical 
Medicine (BNI) in partnership with the European Mobile Laboratory (EMLab). They 
were taken from EMLab sites in Coyah and Guéckédou (Guinea) during the 2013-2016 
Ebola virus outbreak in West Africa. During my PhD I deployed to Coyah as a Team 
Leader to facilitate diagnostics and retrieval of these samples. The aim of these 
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laboratories was to provide Ebola diagnostics to the adjacent Ebola Treatment Centre 
(ETC) and surrounding areas.  
 
At the ETC, 10 ml of blood was taken from a patient suffering from acute symptoms. 
50 l EDTA-whole blood was inactivated in the glove box via the addition of 560 l of 
both AVL (Anti-Viral Lysis) and ethanol. Other bodily fluids were accepted (urine, 
breast milk, semen) for which 140 l of the original sample was required. Additionally, 
oral swabs were taken from community deaths which were suspended in solution prior 
to being treated in the same way as urine. This was done in order to track the spread 
of the virus. 
 
As this thesis continued, more samples were procured for analysis beyond the ones I 
processed in Guinea and transported to Liverpool. Therefore, each chapter starts with 
a table indicating the samples involved.  
 
2.2 Ebola diagnostics  
 
2.2.1 Virus inactivation and RNA extraction 
RNA was extracted from EDTA-whole blood using the QIAamp Viral RNA Mini Kit 
(Qiagen) protocol. Following the addition of ethanol, the sample was vortexed and 
incubated for 10 minutes. Then, the ethanol was added and mixed again. Once 
inactivated, the samples were removed from the glove box securely into a bucket of 
bleach and transferred into the extraction room.  
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630 l of this solution was applied to a column in a 2 ml collection tube and 
centrifuged at 8000 rpm for 1 minute. The filtrate was discarded, and this step 
repeated. After the second centrifugation, 500 l Buffer AW1 was added to the 
column and spun again. This filtrate was discarded and 500 l of Buffer AW2 added. 
This was centrifuged at 14 000 rpm for 3 minutes. Following the discarding of the 
filtrate, 60 l of Buffer AVE was added to the column and incubated for 1 minute. This 
was then centrifuged at 8000 rpm for 1 minute and the eluate used for PCR or stored 
at -20 C until use. Here the quality and quantity of the RNA was assessed by 
Nanodrop (Thermo Scientific).   
 
2.2.2 Diagnostic RT-PCR for Zaire ebolavirus 
EBOV RNA was detected using the RealStar Zaire Ebolavirus RT-PCR kit version 1.0 
(Altona Diagnostics, Hamburg, Germany), using the SmartCycler II system (Cepheid) or 
Rotor-Gene Q system (Qiagen). These systems produced very similar cycle thresholds 
(Cts) when compared (Rieger et al., 2016). This kit includes an internal control (IC), 
which serves as a control of the nucleic acid extraction procedure.  
 
Briefly, 20 l of Master Mix is added to 10 l sample or control and mixed thoroughly. 














Hold 1 - 55 C 20:00 
Denaturation Hold 1 - 95 C 2:00 
Amplification Cycling 45 
- 95 C 0:15 
 58 C 0:45 
- 72 C 0:15 
  
2.2.3 Testing for Plasmodium spp. via an immunochromatographic assay 
During viral inactivation, 15 l of the blood sample was isolated for use in a BinaxNow 
Malaria (Alere) rapid diagnostic test (RDT) for Plasmodium spp. This blood sample was 
transferred onto the sample pad and 2 drops of Reagent A added below. This caused 
the sample to run up the length of the test strip. At this point, 4 drops of Reagent A 
was added to the second reagent pad. The RDT was then closed and left for 15 
minutes. The interpretation of the results was clear, and a band would appear if the 




Figure 2.1: Interpretation of Plasmodium spp. rapid diagnostic test (BinaxNOW, 
Alere). T1 positive – positive result for P. falciparum; T2 positive – positive result for P. 
vivax, P. malariae or P. ovale, or a mixture of two or more of those species; T1 + T2 




2.3 qRT-PCR techniques 
 
2.3.1 DNA removal and sample clean-up 
TURBO DNase (Ambion, Thermo Scientific) was used for the pre-treatment of samples. 
Equimolar concentrations of samples were treated with 2U of TURBO DNase for 15 
minutes at 37 C, before heating to 95 C for 5 minutes and then cooled on ice. For 
clean-up, the RNEasy MinElute kit (Qiagen) was used. Samples treated with DNase 
were incubated with 350 l Buffer RLT (Qiagen) for 10 minutes and then 350 l 70% 
molecular grade ethanol added and mixed thoroughly.  
 
This solution was transferred to RNEasy MinElute spin columns cooled at 2-8 C prior 
to use and the manufacturer’s instructions followed. The resulting purified RNA was 
eluted in 14 l nuclease-free water (Qiagen) and concentrations (ng / l) estimated 
using a Nanodrop 2000. Samples were diluted to equimolar concentrations prior to 
downstream activity.  
 
2.3.2 RT2 Profiler PCR array: Inflammatory cytokines and receptors 
To profile the abundance of mRNA corresponding to the inflammatory response the 
RT2 Profiler PCR array: Inflammatory cytokines and receptors (Qiagen, PAHS-011Z) was 
used. ABI Fast 96-well plates (Life Technologies) were prefilled with lyophilised 
commercial assays targeting 84 genes associated with the human inflammatory 
response. The full list can be found in Table 2.2 and Appendix 7.3. Each well contains 
forward and reverse primers and probes targeting the mRNA of these genes.  
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For each RNA sample, a genomic DNA elimination mix was prepared. This comprised of 
500 g RNA, 2 l Buffer GE and enough RNase-free water to bring the total volume up 
to 10 l. This mixture was incubated for five minutes at 42 C and then placed on ice 
for a minimum of 60 seconds.  
 
A reverse-transcription mix was prepared consisting of 4 l 5x Buffer BC3, 1 l Control 
P2, 2 l RE3 Reverse Transcriptase Mix and 3 l RNase-free water. This 10 l mixture 
was added to each genomic DNA elimination mix and mixed gently. Following this 
addition, the mixture was incubated for 15 minutes at 42 C, then for 5 minutes at 95 
C to stop the reaction. 91 l RNase-free water was then added to each reaction and 
mixed thoroughly on ice.  
 
In a 5 ml tube, 1350 l 2x RT2 SYBR Green Mastermix was added to the 102 l cDNA 
synthesis reaction and 1248 l RNase-free water. Using a multi-channel pipette, 25 l 
added to the PCR array with thorough mixing to help suspend the lyophilized primer 
mix. This 96-well plate was then sealed and centrifuged for 1 minute at 1000 g at room 
temperature in order to remove any bubbles before qRT-PCR.  
 
Ct values for all wells were exported to a blank Excel spreadsheet. Data analysis was 
then conducted at QIAGEN’S GeneGlobe Data Analysis Center using a software-based 
tool that allows the analysis of RT-PCR data (QIAGEN, 2016). The real-time PCR 
modules transformed the Ct values to calculated results for gene expression.  
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Table 2.1: Full list of gene targets tested using a focussed, gene specific profiler array 
for the human inflammatory response. Functional categories are shown alongside the 
accompanying gene target list.  
Chemokines C5, CCL1 (I-309), CCL11 (eotaxin), CCL13 (MCP-4), CCL15 
(MIP-1d), CCL16 (HCC-4), CCL17 (TARC), CCL2 (MCP-1), 
CCL20 (MIP-3a), CCL22 (MDC), CCL23 (MPIF-1), CCL24 (MPIF-
2 , Eotaxin-2, MPIF-2, Eotaxin-2), CCL26 (eotaxin-3), CCL3 
(MIP-1A), CCL4 (MIP-1B), CCL5 (RANTES), CCL7 (MCP-3), 
CCL8 (MCP-2), CX3CL1, CXCL1 (GRO1, GROa, SCYB1), CXCL10 
(INP10), CXCL11 (I-TAC, IP-9), CXCL12 (SDF1), CXCL13, CXCL2 
(GRO2, GROb, SCYB2), CXCL3, CXCL5 (ENA-78, LIX), CXCL6 
(GCP-2), CXCL9 (MIG). 
Chemokine Receptors CCL13 (MCP-4), CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR8, 
CX3CR1, CXCR1 (IL8RA), CXCR2 (IL8RB). 
Interleukins 
 
IL13, IL15, IL16, IL17A, IL17C, IL17F, IL1A, IL1B, IL1RN, IL21, 
IL27, IL3, IL33, IL5, IL7, CXCL8, IL9. 
Interleukin Receptors IL10RA, IL10RB, IL1R1, IL5RA (CD125), IL9R. 
Other Cytokines 
 
AIMP1 (SCYE1), BMP2, CD40LG (TNFSF5), CSF1 (MCSF), CSF2 
(GM-CSF), CSF3 (GCSF), FASLG (TNFSF6), IFNA2, IFNG, LTA 
(TNFB), LTB, MIF, NAMPT, OSM, SPP1, TNF, TNFSF10 (TRAIL), 








2.3.3 Targeted qRT-PCR 
Primers were designed by NCBI/Primer-BLAST targeting 2 exons that spans an intron 
based on the alignments of all available RNA transcript sequences of each of the 10 
human genes from the transcriptome database AceView (mRNAs from GenBank or 
RefSeq, and single pass cDNA sequences from dbEST and Trace). Primers were then 
synthetized by Eurofin Genomics (Ebersberg, Germany). 
 
The optimised conditions for the one-step singleplex RT-qPCR assay were as follows: 5 
μl of RNA added to a reaction mixture of 2X iTaq universal SYBR green reaction mix 
(2X) and iScript Reverse transcriptase (2X)(Bio-Rad), 100 nM of each primer in a final 
reaction volume of 20 μl. The one-step singleplex RT-qPCR was run on the CFX 96™ 
real time PCR machine (Bio-Rad). The following thermal cycling parameters were used: 
1 cycle of RT for 10 min at 50°C followed by 1 cycle of polymerase activation and DNA 
denaturation at 94°C for 1 minute, and 40 cycles of denaturation at 94°C for 10 
minutes and annealing/extension at 60°C for 30 minutes.  
 
The measurement of number of RNA copies was determined using a previously 
developed formula. The formula gives the molecules per µl (N), if the concentration of 
the cRNA (C) is known in relation to the fragment size (K) multiplied by a factor derived 
from the molecular mass and the Avogadro constant:    
 
N (molecules per ul) =   C (cRNA µg/µl)      182.5 x 1013 




The efficiency and dynamic range of the respective singleplex assays were established 
by amplifying five 10-fold dilutions from 107 to 103 of RNA transcripts of each gene. 
Each dilution was amplified in triplicate in separate runs by each gene. 
 
2.4 In vitro tissue culture techniques 
 
2.4.1 Routine culture of THP-1 cells 
THP-1 cells are semi-adherent/suspension cells and were acquired from the ECACC. 
Here, an authenticated, mycoplasma and bacteria-negative cell bank was established 
by ECACC technicians. All cultures were started from this authenticated stock to 
ensure standardisation of experiments across the project. For passaging, cells were 
counted using plastic disposable C-Chip Neubauer cytometers (NanoEnTek) and 
reseeded at a density of 0.1-0.3x10e+6 cells per ml. Cultures were maintained 
between 0.3x10e+6 and 2x10e+6 in RPMI media supplemented with GlutaMAX 
(Thermo Scientific) at 10% for routine culture. 
 
2.4.2 Generation of PMA-differentiated THP-1 macrophage-like cells 
Naïve THP-1 cells are semi-adherent and morphologically and functionally similar to 
monocytes and can be differentiated into macrophage like cells using Phorbol-12-
myristate (PMA, Sigma-Aldrich) (Qin, 2012; Genin et al., 2015). PMA was diluted in 
DMSO to a working concentration of 1 g/ml, then to a final concentration of 5 ng/ml 
in RPMI supplemented with 10% media. Cells were suspended in complete growth 
media with additive 5 mg/ml PMA to an appropriate concentration. After thorough 
mixing by inversion, cells were added to flasks to form 80% to 90% confluent layer of 
cells. The growth of PMA differentiated THP-1 cells will be inhibited, therefore 
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activation was initiated after the required cell volume was reached. 24 hours after the 
addition of PMA, cells were rinsed twice with PBS (Thermo Scientific) and fresh 
complete RPMI growth media added. Cells were rested for 72 hours before infection 
took place, during which time the cells changed in their morphology, becoming 
adherent.  
 
Cell culture in CL4 conditions provided challenges in the form of high levels of 
formaldehyde residues and cytotoxic chemicals. The result is that cell growth was 
maintained in flasks with plug-sealed caps and locked within sealable boxes. In 
negative controls, cell viability remained high (> 90%), as evaluated using Trypan Blue 
(Sigma-Aldrich) and manual counting using a cytometer.  
 
2.4.3 Viral infection 
The EBOV Makona variant was obtained from the European Mobile Laboratory and 
was isolated during the laboratory response to the 2013-2016 West African outbreak. 
This isolate was designated Ebola virus/H. sapiens-wt/GIN/2014/Makona-Gueckedou-
C05. This isolate has been cultured in Vero cells. Virus was quantified by a modified 
TCID50 method.   
 
From these infected cells, viral RNA was extracted as described in 2.2.1 and quantified 




2.5 Nanopore sequencing 
 
2.5.1 RNA preparation 
The cDNA-PCR Sequencing Kit (SQK-PCS108) was used to prepare samples for MinION 
(Oxford Nanopore) sequencing. The samples were RNA extracts from retrieved from 
the EMLab as described previously. RNA extracts were quantified using a Qubit 
(Thermo Scientific) where the Broad Range RNA kit (Abi, Thermo Scientific) was used. 
A Nanodrop 2000 (Thermo Scientific) assay for RNA concentration estimation was 
performed and ratios at 260/280 nm and 260/230 nm calculated to determine sample 
purity. 50 ng was transferred into a DNA LoBind tube and the volume adjusted up to 9 
l with nuclease-free water. This was mixed via flicking of the tube and spun down 
using a microfuge. 
 
2.5.2 Reverse transcription and strand-switching 
To the previous solution, 1 l VNP and 1 l 10mM dNTPs were added and mixed 
gently. This solution was incubated at 65 C for five minutes and then cooled. In a 
separate tube, a master mix was composed consisting of 4 l Superscript IV buffer, 1 l 
RNaseOUT, 1 l 100 mM DTT and 2 l Strand-Switching Primer (SSP). This mixture was 
added to the annealed mRNA and mixed thoroughly. This mixture was incubated at 42 
C for two minutes and then 1 l of SuperScript IV Reverse Transcriptase was added to 
bring the total volume for each sample up to 20 l. This was mixed gently and spun 
down before being incubated following the conditions in Table 2.3. 
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Table 2.3: Heating conditions for reverse transcription. 
Function Length (minutes) Temperature (C) Number of cycles 
Reverse transcription 10 50 1 
Strand switching 10 42 1 
Heat inactivation 10 80 1 
Hold - 4  - 
 
Within the reaction tube, 25 l 2x LongAmp Taq Master Mix, 1.5 l cDNA PRM (cPRM) 
and 18.5 l nuclease-free water were added to 5 l reverse-transcribed RNA sample. 
Four PCR reactions are carried out for each RNA sample and then pooled. This solution 
was involved in an amplification step following the following conditions (Table 2.4). 
  
Table 2.4: Reverse transcription conditions using a CFX96 (Bio-Rad). * In order to 
maximise read length an extension time of two minutes and 30 seconds was used.  
Function Length (seconds) Temperature (C) Number of cycles 
Initial denaturation 30 95 1 
Denaturation  15 95 18 
Annealing 15 62 18 
Extension 50/kb* 65 18 
Final extension 6 minutes 65 1 
Hold - 4 - 
 
The four PCR reactions for each sample were pooled and added to 160 l AMPure XP 
beads before a five minute incubation on a rotator mixer at room temperature (RT). 
The samples were spun down and pelleted using a magnetic rack, allowing the 
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supernatant to be removed. The beads were washed using 70% ethanol twice. After 
the 70% ethanol was removed for the second time, the beads were allowed to dry 
briefly. The beads were then resuspended in 21 l Rapid Annealing Buffer (RAB) and 
incubated on the rotator mixer for 10 minutes at RT. After this, the beads were 
pelleted again on the magnetic rack and this time the eluate removed and retained.  
 
2.5.3 Adapter addition and AMPure clean up 
1 l of this amplified DNA was quantified using the Qubit. 500 ng of cDNA was taken 
and made up to 20 l with RAB. To this, 5 l of cDNA Adapter Mix was added, and this 
solution spun down. This was followed by a five-minute incubation on a rotator mixer 
at RT. 20 l of resuspended AMPure XP beads were then added and the solution 
allowed to pellet on a magnetic rack. The supernatant was removed and 140 l ABB 
buffer added, allowing the beads to resuspend. This process was repeated once more. 
After pelleting for the second time, the beads were resuspended in 12 l Elution Buffer 
(ELB) and incubated using the rotator mixer for 10 minutes at RT. Following this, the 
beads were pelleted again and 12 l of eluate removed and retained. This solution was 
stored on ice until sequencing.  
 
2.5.4 Priming and loading of flow cells 
In order to prime the flow cells for use, a very small volume of liquid was removed 
from the priming port, in order to determine that no bubbles were present. 576 l RBF 
was then added to 624 l nuclease-free water to form a priming mix. 800 l of this was 
loaded into the flow cell via the priming port.  
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In order to load the library, 12 l DNA library was added to 35 l RBF, 2.5 l nuclease-
free water and 25.5 l LLB. The remaining 200 l of the priming mix was loaded via the 
SpotON sample port followed by 75 l of the sample in a drop by drop delivery 
method. Here, care must be taken in order to prevent the introduction of any bubbles, 
as the effect of this could be substantial. After this, the sequencing run can begin using 
MinKNOW software (Oxford Nanopore).   
 
2.6 Next generation sequencing  
 
2.6.1 DNA removal and clean-up 
RNA samples that went on to be Sequenced on a HiSeq 2500 or 4000 (Illumina) were 
first treated with TURBO DNase (Ambion, Thermo Scientific). Samples were treated 
with 2U of TURBO DNase for 15 minutes at 37 C, before heating to 95 C for 5 
minutes and cooled on ice. Subsequently, the RNEasy MinElute kit (Qiagen) was used. 
DNase-treated samples were added to 350 l of Buffer RLT (Qiagen) and left for 10 
minutes. Then, 350 l 70% molecular grade ethanol was added and the sample mixed.  
 
These samples were transferred to RNEasy MinElute spin columns (pre-cooled to 2-8 
C) and the protocol followed. Purified RNA was eluted in 14 l Nuclease Free Water 
(Qiagen).  
 
2.6.2 Illumina library preparation 
This was performed by colleagues at the Centre of Genomic Research. Illumina 
libraries were prepared using the DNase-treated RNA using the Epicentre ScriptSeq v2 
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RNA-seq library preparation kit and performing 10 to 15 cycles of amplification. 
Libraries were purified using AMPure XP magnetic beads (Ambion). Each library was 
quantified using Qubit (Thermo Scientific) using the DNA High Sensitivity Kit, the size 
distribution was assessed using the Agilent 2100 Bioanalyser, and the final libraries 
were pooled in equimolar ratios. The quantity and quality of each pool were assessed 
with the Bioanalyzer and subsequently by qPCR using the Illumina library 
quantification kit (Kapa) on a Roche Light Cycler LC480II system according to the 
manufacturer’s instructions. 
 
2.6.3 HiSeq 2500 loading 
The template DNA was denatured according to the protocol described in the Illumina 
User Guide and loaded at 12 pM. To improve sequencing quality control, samples were 
spiked with 1% PhiX, functioning as an IC viral RNA. The sequencing was undertaken on 
the Illumina HiSeq 2500 with version 4 chemistry, generating 2 x 125-bp paired-end 
reads. Base calling and demultiplexing of indexed reads were performed by using 
Casava version 1.8.2 (Illumina) to produce all the sequence data in fastq format.  
 
2.6.4 Sequencing of guinea pig samples 
Animal experiments were performed as described in Dowall et al. (2014). Pooled 
spleens of six infected guinea pigs were treated as above but the pool of libraries was 
sequenced on one flow cell of the MiSeq at 2 × 150 based paired-end sequencing with 




2.7 Bioinformatics analysis 
 
2.7.1 Next generation sequencing data analysis in GALAXY (Penn State) 
GALAXY is an online system that provides a user-friendly interface, accessing a library 
of command line scripted algorithms for the analysis of next generation sequencing 
(NGS) data.  
 
The raw fastq files were trimmed to remove Illumina adapter sequences by using 
Cutadapt version 1.2.1. The option ‘-O 3’ was set, so the 3’ end of any reads which 
matched the adapter sequence over at least 3 bp was trimmed off. The reads were 
further trimmed to remove low-quality bases, using Sickle version 1.200 with a 
minimum window quality score of 20. After trimming, reads shorter than 10 bp were 
removed. If both reads from a pair passed this filter, each was included in the R1 
(forward reads) or R2 (reverse reads) file. If only one of a read pair passed this filter, it 
was included in the R0 (unpaired reads) file. 
 
2.7.2 Mapping of reads and fusion events 
The resulting R1/R2 sequence read pairs were initially mapped to the human reference 
genome GRCh38 (ftp://ftp.ensem-bl.org/pub/release-
77/fasta/homo_sapiens/dna/Homo_-apiens.GRCh38.dna_sm.primary_assembly.fa.gz) 
using Tophat2 version 2.1.0 using paired-end mapping, which used the short-read 
mapper Bowtie2 (Langmead and Salzberg, 2012). Those reads that did not map to the 
human genome were then pooled and mapped again to a list of known human 
transcripts again using Bowtie2. Read counts were generated from these alignments 
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using HTSeq-count and a gtf file, which informed where the gene boundaries sit on the 
reference genome. In order to detect fusion events in the EBOV genome samples were 
mapped to EBOV Makona-Gueckedou-C05 using Tophat2 and the fusion search 
enabled. The anchor length was set to 20, meaning that a supporting read had to map 
both sides of a fusion event by 20 bases. Reads containing fusion events that mapped 
to multiple parts of the genome were excluded (Kim and Salzberg, 2011).  
 
2.7.3 Identification of differentially expressed genes using EdgeR 
EdgeR calculates fold change in a transcript comparing hospitalised fatalities to 
hospitalised survivors and that acutely ill cohort to convalescent controls. The 
normalised read counts generated by HTSeq-count were imported into R. EdgeR uses 
negative binomial distribution in order to model read counts and provide a p value as 
well as a false discovery rate (FDR), and therefore the adjusted statistical significance 
of supposed differences (Robinson et al., 2010). An absolute log2(fold change) > 1 was 
considered to be differentially expressed, with an FDR < 5%.   
 
2.7.4 Identification of microorganism transcripts 
This was performed by colleagues at the Centre of Genomic Research. Sequences that 
did not align to either the human genome or human transcriptome were pooled, but 
the size of the data set (~1 TB of fastq reads) required them to be pre-processed first 
by the Trinity read normalization software to reduce the memory requirements and 
runtimes prior to de novo assembly using Trinity (Haas et al., 2013). The assembled 
data from Trinity were first manually checked to determine that the EBOV genome had 
been assembled before all the reads were checked for matches using Diamond BLASTX 
analysis against the nonredundant protein database (Buchfink et al., 2015). For each 
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transcript, the best hit was retained and the protein name and organism for that hit 
was associated with the transcript using in-house scripts. Quality and primer trimmed 
reads were used as input for MetaPhlAn 2 for estimating genome coverage of bacterial 
species for each sample. In general, for viral species a 20% mapping to a transcriptome 
was adopted as a threshold for positive identification.  
 
2.7.5 KEGG analysis  
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database consist of proteins, 
genes and their functional properties (Kanehisa and Goto, 2000). Therefore, canonical 
pathways can be highlighted once linked to a dataset via determining which pathways 
are the best fit using the genes that are most represented in any one pathway. When 
this tool was employed the default settings were used and the Homo sapiens (HSA) 
pathway database selected and an adjusted p value of 0.05 chosen as cut-off.   
 
2.7.6 Quasispecies analysis 
QuasiBAM, developed by Public Health England, was used to measure the genome 
diversity in the generated bam files. This tool functions by comparing the assembled, 
mapped reads against a reference genome and identifying the minor and major 
variants, i.e. those nucleotide changes occurring at a high and low frequency 
respectively.  
 
2.7.7 Nanopore data analysis using GALAXY (Penn State) 
MinKNOW outputs sequences into fastq and fast5 files. Using the fastq files, reads 
were concatenated as single-end reads are generated and dumped when the number 
of reads reaches 4000. These were trimmed using Porechop v0.2.3, in order to cope 
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with the “noisy” data generated using Nanopore (Wick et al., 2017), and mapped to 
the EBOV genome using BWA-MEM, for which Oxford Nanopore has created an 
analysis mode which fits well with the type of data generated by this platform – 
Nanopore 2D-reads mode (C. Jain et al., 2018). These files were removed and 
subsequently mapped to the human genome. These generated bam files were aligned 
to gtf files - Homo sapiens GRCh38.77 or Zaire ebolavirus ncbiGene. The transcription 
profiles of hospitalised survivors and hospitalised fatalities were compared using 
DESeq2.  
 
2.7.8 Ingenuity Pathway Analysis  
Ingenuity Pathway Analysis (IPA; Qiagen) is a toolkit available for the analysis of gene 
and protein expression data. Fold change data is uploaded and annotated in the 
software. The software analyses for over-represented canonical pathways, functional 
groups and disease groups. Additionally, activation score (z-score) is calculated to 
determine the level of pathway activation using the cumulative fold increase or 
decrease of the genes aligned to each pathway. This allows the host response to be 
analysed and patient groups compared.  
 
2.7.9 Digital cell quantification 
In order to determine predicted immune cell profiles using transcriptomic data, the R 
package ComICS was used (Altboum et al., 2014). The default parameters were used 
with 500 repeats and a split ratio of 50% on an input dataset of fold changes compared 
to convalescent controls (hospitalised_fatalities to controls and hospitalised_survivors 
to controls). All 207 cell types were analysed. The resulting data provided a predicted 
mean relative abundance as well as the standard deviation of the mean. To determine 
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cell types that were significantly different from zero, a standard t-test was performed 
with a p value cutoff of 0.05. Definition of immune subsets is based on ImmGen 
database information and thus represents previously validated mouse equivalents to 
human immune cells (Auffray et al., 2009; Villadangos and Shortman, 2010; Haniffa et 
al., 2012).  
 
2.8 Statistical analysis 
Statistical analyses were performed in R, SPSS 25 and GraphPad Prism version 6.0 and 
described here.  
 
2.8.1 General linear model (GLM) and analysis of variance (ANOVA) 
As part of the multi-variate analysis, a GLM was generated in order to determine which 
variables could be potentially influencing patient outcome. This allows multiple models 
of regression to be run simultaneously in order to determine data patterns and 
potential correlates of prognosis.  
 
An ANOVA allows multiple groups and/or variables to be compared simultaneously 
and their variances compared. Multiple comparisons are corrected for using post-hoc 
analyses. This allowed the testing of the potential effects variables exhibit on datasets.  
 
2.8.2 Principle component analysis (PCA)  
PCA uses an algebraic orthognanol transformation to covert variables of potentially 
correlating data into linearly uncorrelated values or principle components. The number 
of variables is reduced allowing entire datasets to be described in terms of relatedness 
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between populations. The first component analysis is the most sensitive and each one 
thereafter requires more transformation and is therefore less sensitive. By only using 
two or three components, very complex data can be simplified, compared and 
separated.  
 
2.8.3 Linear discriminant analysis (LDA) 
An LDA uses Fisher’s linear discriminant to determine linear combinations of features 
that can separate variables, similarly to an ANOVA. However, an LDA is able to 
separate categorical dependent variables – in this case patient outcome – according to 
continuous independent variables. In order to visualise this analysis, bi-plots and 






Chapter 3: Viral quasispecies and the 
impact of genome variation on patient 
outcome during Ebola Virus Disease 
 
3. 1 Introduction 
 
3.1.1 2013-2016 outbreak of EBOV-Makona 
The 2013-2016 EVD outbreak in West Africa was unprecedented in scale, allowing an 
in-depth analysis of viral adaptation within naturally-infected humans and the 
observation of previously unknown aspects of EBOV biology. The variant of EBOV from 
this outbreak was given the name EBOV-Makona, after a river running through Guinea, 
Sierra Leone and along the border of Liberia, the three most-affected countries (Kuhn 
et al., 2014). High-resolution genome analysis was used to analyse consensus EBOV 
sequence and nucleotide variation within (intra) and between (inter) individuals (Gire 
et al., 2014; Carroll et al., 2015; Park et al., 2015). Fitness, as measured by the ability of 
a virus to replicate with high fidelity and adapt to multiple host pressures, plays a 
major role in determining viral load and the definition of each patient’s disease course.  
 
Investigations into Makona compared to other EBOV isolates have identified few 
differences in cell entry (Hofmann-Winkler et al., 2015), immune response (Bosworth 
et al., 2017) and pathogenicity (Marzi et al., 2018), however, the latter is disputed 
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(Wong et al., 2016; Bosworth et al., 2017). These potential differences highlight the 
importance of the thorough study of this isolate.  
 
3.1.2 EBOV replication leads to the generation of viral quasispecies 
EBOV RNA genome replication fidelity is determined by the inherent error rate 
induced by the viral RNA-dependent RNA polymerase (the L protein). Additionally, 
there exist potential genome modifications resulting from errors induced by cellular 
proteins involved in RNA processing, including Adenosine Deaminases Acting on RNA 
(ADARs) (inducing an A to G transition) and APOBEC (C to U transition) (Martínez and 
Melero, 2002; Sheehy et al., 2002; Suspene et al., 2011). Any perturbation in the 
fidelity of genome replication that increases the rate of mutation can lead to error 
catastrophe where synonymous and non-synonymous changes lead to a loss in viral 
RNA synthesis and viral protein function. This can be exploited therapeutically where 
drugs such as ribavirin can be used to drive the replication of RNA viruses towards 
being less fit (Crotty et al., 2001; Severson et al., 2002; Graci and Cameron, 2006; 
Aljabr et al., 2016).  Such errors lead to the generation of viral quasispecies. This 
concept refers to the viral population existing as a consensus viral genome surrounded 
by other genomes of fluctuating nucleotide variation (Chapter 1, Figure 1.4) (Domingo 
et al., 2012). Whilst the generation of quasispecies can be exploited therapeutically, it 
also has benefits for the virus as it allows the successful navigation of population 
bottlenecks, which can be induced by zoonotic transmission, the host immune 




3.1.3 Persistence of infection 
The 2013-2016 outbreak has shown that certain individuals experience persistent 
infections following EVD. A number of patients have remained EBOV-positive for 
extended periods in certain body fluids after testing negative in their blood via qRT-
PCR. During routine diagnostic testing for the European Mobile Laboratory (EMLab), a 
study was launched that followed male survivors into their convalescence, testing their 
semen, urine and saliva for EBOV RNA (Sissoko et al., 2017). During this study, the 
clearance time for EBOV in seminal fluid was seen to be as long as 13 months, with the 
first confirmed case of sexual transmission of the virus being recorded (Christie et al., 
2015). This is unlikely to be the first time this has occurred, simply the first time it was 
able to be established with confirmed laboratory diagnosis and genetic analysis. For 
example, EBOV was found in the semen of an individual following a laboratory 
accident at Porton Down in 1976 (Emond et al., 1977). Additional cases show viable 
EBOV in the aqueous humor of the eye three months after viral clearance (Varkey et 
al., 2015).  
 
There are several hypotheses as to how this persistence is maintained but it is not well 
understood. One such hypothesis is the formation of defective interfering (DI) 
genomes. These are truncated viral genomes capable of interrupting normal viral 
replication via the competition for viral resources, hence resulting in a reduction of 
virus infectivity (as reviewed by Marriott and Dimmock, 2010). These shorter genomes 
contain intact 3’ and 5’ ends (and replication signals) but include substantial deletions 
of coding (and non-coding) sequence. Most commonly identified in in vitro 
experiments, DIs have been detected in a number of viruses including EBOV (Calain et 
al., 1999) and measles (as reviewed by Rima and Duprex, 2005). Although less 
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common, DIs have also been identified in naturally-infected humans, for example in 
patients with acute Dengue (Li et al., 2011) and chronic Hepatitis C (Noppornpanth et 
al., 2007).     
 
The production of DIs can be compared to the modulation of viral gene expression 
observed in HIV and HPV among others (Carl et al., 2002; Lace et al., 2008). This 
modulation also has the ability to produce persistent infections. Immune modulation 
may also be involved in maintaining these infections, as suggested in Hepatitis B virus 
(HBV) and HIV-1, among many others (Stoop et al., 2005; Rustagi and Gale, 2014).  
 
3.1.4 RNA-sequencing techniques 
Illumina RNA-sequencing (RNA-seq) has been used successfully to study viral 
populations for many years. However, the technique is not infallible. The generation of 
short reads makes the study of certain aspects of EBOV biology more challenging. 
Nanopore sequencing, on the other hand, produces long reads many thousands of 
nucleotides in length. This has the potential to encompass an entire viral genome in 
one read and has been shown to be effective in viral sequencing (Quick et al., 2016; 
Kafetzopoulou et al., 2018). Here, long reads could allow for the investigation of viral 
quasispecies and DIs with more confidence than using reads generated by an Illumina 
platform.    
 
3.1.5 Objectives and hypotheses 
The aims of this chapter are to understand the potential factors influencing patient 
outcome of EVD-Makona and identify certain risk groups. RNA extracts have been 
obtained from the EMLab in Guinea and categorised according to a number of factors 
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including their age and sex. Also, the minor variants observed along the EBOV genome 
have been considered and therefore the generation of viral quasispecies. It is possible 
that these populations will differ between hospitalised fatalities and survivors. This 
could be in terms of specific mutations associated with fatalities and therefore an 
increase in pathogenicity, or a more general trend at the viral population level in terms 
of variation. The 2013-2016 outbreak in West Africa has highlighted the ability of the 
virus to persist within certain body compartments of infected individuals for extended 
periods of time (Varkey et al., 2015; Sissoko et al., 2017), with one explanation being 
DIs. These are predicted to be found in experimentally infected cells, and if found in 
patient samples, could offer explanation as to how this persistence occurs. The 
sequencing of RNA extracts from infected cell lines and diagnostic samples has also 
provided an opportunity to compare Illumina and Nanopore RNA-sequencing. Each has 
their advantages, with different uses in particular settings.   
 
3. 2 Results 
 
3.2.1 Viral load can be used as a predictor of patient outcome 
To identify changes in the viral genetics of EBOV during infection, blood samples from 
infected patients were analysed via RNA-seq. These samples were collected by the 
EMLab and myself in Guinea during 2014 and 2015. The samples were taken with the 
foremost aim of diagnosing the presence of EBOV using quantitative (q)RT-PCR, which 
was then used in patient management in the Ebola Treatment Centre (ETC). For this 
purpose, RNA was extracted in the setting of the EMLab in Guinea. Blood samples 
were taken from acutely ill patients, as well as oral swabs from deceased individuals in 
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the community. Discarded samples were then held in an archive and used in this study 
under the auspices of the EVIDENT project– Ebola Virus Disease correlates of 
protection, determinants of outcome and clinical management. These discarded 
samples were then analysed by Illumina RNA-seq to identify and quantify viral 
RNA. Following sequencing of 138 individual samples from individual patients, strict 
selection criteria were employed to identify and remove datasets from samples that 
showed evidence of having degraded RNA (expected from field sample collection) 
(Table 3.1). From an initial set of 138 individual sequenced samples from separate 
patients, application of these selection criteria led us to discard 26 and analyse the 
data from 112 unique patients: hospitalised survivors (n = 24) and hospitalised 
fatalities (n = 88). In the context of this thesis this is defined as follows: blood was 
collected from hospitalised individuals at a time when the outcome for these patients 
was unknown and subsequently recorded as they either succumbed to a fatal infection 
or survived EVD. As observed in previous outbreaks, the viral load of individuals who 
went on to die from EVD was higher than in survivors (Figure 3.1).  
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Table 3.1: Summary of patients involved in this study. These have been split according 
to sample type and patient outcome. Here, patient age and EBOV Ct are described by 










N 88 24 16 24 
% Male 46.3 31.0 93.8 29.1 
Age 
(years) 
Range 2 mo – 78 10 mo – 68 18 – 40 1 - 70 
Mean 29.5 32.1 33.1 30.0 
EBOV Ct 
Range 12.1 – 26.6 15.8 – 31.6 NA 12.4 – 31.9 






Figure 3.1: EBOV viral load is significantly higher in individuals who die from EVD, 
compared to those who survive. Here, the reciprocal EBOV cycle threshold (Ct) value (a 
proxy for viral load) is compared between acute sufferers of EVD who go on to survive 
or die. Mann-Whitney U test performed using Prism 7 GraphPad (CA, USA) to compare 






























Importantly, there was no significant difference in the time between symptom onset 
(as reported by the patient) and taking of the sample during acute illness. The mean 
time to the onset of symptoms for the acute survivors was 6.4 days and for acute 
fatalities was 5.9 days with a range of 2–19 and 2–22 days, respectively (Figure 3.2). 
Here, time between symptom onset and sample procurement was used as a proxy for 
length of infection. This is an important factor to consider when comparing groups of 
infected patients. A prediction could be made that the longer an individual has been 
infected, the more viral replication has occurred, thus widening the viral quasispecies 
and increasing genome variation. Certain patients were not clinically fit to be providing 
this information, whilst others claimed to have had acute symptoms for many years. 
Therefore, strict inclusion criteria were established, with individuals claiming to be 
symptomatic for more than 30 days not included in the analysis as this is likely to be 
due to co-morbidities. This cut-off was informed by the incubation period of EBOV and 
necessary due to the outlying patients – i.e. one individual claimed to be suffering 




Figure 3.2: Patient groups did not differ in terms of time between symptoms onset 
and sample procurement. Mann-Whitney test was performed and no significant 






















3.2.2 Potential factors influencing patient outcome 
Other criteria were present on the admission form to the ETC, including EBOV Ct value, 
patient sex, age, response to malaria rapid diagnostic test (RDT) and their geographic 
location. Analysing this information together allowed the construction of a general 
linear model (GLM) in order to assess which factors, if any, were found to influence 
patient outcome. Within these samples, age appeared to have no impact on patient 
survival (Figure 3.3A, p > 0.1), along with sex (Figure 3.3C, p > 0.1). Despite this not 
being statistically significant, a higher proportion of women went on to die from EVD. 
As mentioned previously, EBOV Ct was significantly lower (demonstrating a higher viral 
load) in fatal patients (Figure 3.2), as well as those suffering with acute malaria as a co-




Figure 3.3: Potential factors influencing patient outcome. Patients split by outcome 
into hospitalised fatalities (black) and survivors (grey). General linear model (GLM) 
constructed in order to compare distribution of age (A, p > 0.1), response to 
Plasmodium spp. RDT (B, p = 0.053) and sex (C, p > 0.1) between patient groups. 

























































3.2.7 Comparison of RNA-sequencing techniques 
During the outbreak and my deployment with EMLab, Nanopore sequencing was 
employed for the determination of phylogenetic analysis. This was achieved via the 
use of EBOV-specific amplicons (Quick et al., 2016). This was also performed 
immediately following RNA extraction, ensuring the optimal quality of the RNA, with 
no potential degradation due to freeze-thaw cycles.  
 
In order to determine the further uses for this technique, a transcriptomic approach 
was employed and three samples from hospitalised survivors were compared to three 
from hospitalised fatalities. In order to gain a transcriptomic profile, a PCR cDNA 
sequencing kit was used, employing random primers. This would allow several key 
questions to be answered. For example, (1) can Nanopore sequencing be employed to 
build a consensus EBOV genome using clinical samples? (2) Can long reads from 
Nanopore sequencing elucidate our understanding of viral quasispecies? (3) Can long 
reads truly confirm the presence of DIs as opposed to simply identifying fusion events? 
 
Upon mapping to the EBOV genome, very few samples had substantial coverage. In 
order to attempt to build a consensus genome, all six samples were concatenated and 
mapped again to the EBOV genome, but this still did not provide sufficient coverage. 
Reads following Nanopore sequencing are much longer than Illumina reads, up to 
several thousand base pairs in length. There are very few reads mapping to the 5’ end 
of the genome, with coverage for the L protein being almost non-existent (Figure 
3.4A). Therefore, constructing a consensus genome proved impossible.  
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Comparing a sample sequenced using Nanopore to an Illumina-sequenced run of a 
sample illustrates the extent of the drawbacks of using Nanopore sequencing to gain 
information using partially degraded diagnostic samples (Figure 3.4B). These samples 
are both RNA extracts from diagnostic blood samples that tested positive for EBOV by 
qRT-PCR. Therefore, the further investigation into understanding EBOV was performed 




Figure 3.4: Coverage across the EBOV genome following Nanopore sequencing. All 
reads mapping to EBOV following the sequencing of RNA samples from the extracted 
RNA of the blood of EVD patients (A). This was performed using the MinION. The 
coverage of using Nanopore sequencing (blue line) is much lower when compared to a 





3.2.3 Differences in viral variation between hospitalised fatalities and hospitalised 
survivors 
Investigating the viral genome diversity in patients appeared to reveal some 
fundamental differences between patients with the alternate outcomes. Viral diversity 
was calculated for the patient samples by measuring the minor variants at a threshold 
of 0.05 across the viral genome using a sliding scale of 100 nucleotides. It is likely that 
many factors would be capable of influencing the viral diversity found within a patient, 
including viral load, a patient’s stage of infection and the host immune response. In the 
sample set analysed, there was no correlation between viral diversity and length of 




Figure 3.5: Viral diversity did not correlate with an individual’s length of infection. 
Mean viral diversity was plotted against length of infection, with no significant 
correlation being observed between the two factors. Linear regression performed 
(black line), R2 = 0.025, p = 0.065. Points are colour-coded by patient group, where H_F 
are hospitalised fatalities (red) and H_S are hospitalised survivors (green). Viral 
diversity is a measure of the number of minor variants (at a rate of 0.05 or above) using 
a sliding window of 100 nucleotides along the length of the EBOV genome. 
 
  



































Perhaps surprisingly, as viral load decreased, viral diversity was observed to be higher 
(Figure 3.6A, p < 0.0001). Following on from this, patient groups were compared, 
where the viral diversity in patients who went on to survive infection was significantly 
higher than those who die (Figure 3.6B, p = 0.0019). The samples of a small number of 
community deaths record the highest genome diversity when compared to the 
samples from hospitalised individuals. However, this did not reach a level of statistical 
significance (Figure 3.6B). Any findings drawn from this comparison must be 
considered carefully due to the fact that these patient groups represent different 




Figure 3.6: Relationship between viral load and viral genome diversity. As viral load 
decreases, viral diversity increases (A). Points are colour-coded by patient group, where 
H_F are hospitalized fatalities (red), H_S are hospitalised survivors (green) and C_D are 
community deaths (black). Linear regression performed (black line), R2 = 0.26, p < 
0.0001. Viral diversity is significantly higher in acutely-infected survivors compared to 
fatalities (B). Viral diversity is a measure of the number of minor variants (at a rate of 
0.05 or above) using a sliding window of 100 nucleotides along the length of the EBOV 
genome. One-way ANOVA performed with Holm-Sidak’s corrections for multiple 















































































3.2.4 Variation along the EBOV genome 
After identifying some fundamental differences in viral populations in fatal and non-
fatal EVD patients, the next step was to investigate where along the EBOV genome this 
variation was occurring. A number of RNA viruses have hyper-variable regions that are 
postulated to help in the response to selection pressures – particularly for immune 
evasion (Cane et al., 1994; Delisle et al., 2012; Guan et al., 2012). Therefore, 
investigation into whether the intra-patient variation occurred in discrete regions 
along the EBOV genome was performed. Here, the proportion of minor variants at a 
rate of 0.05 or above were calculated as a proportion of the total coverage. This is 
shown as an average over a sliding window of 100 nucleotides (Figure 3.7). These data 
indicated that variation along the EBOV genome occurs in coding and non-coding 
regions alike. There appear to be clusters of variation at discrete nucleotide positions, 
which differ in hospitalised survivors (Figure 3.7A) in comparison to fatalities (Figure 
3.7B). As suggested previously, the variation appears to be higher in survivors, with 
peaks of variation occurring in viral genes NP and L. Some of the variation along the 
EBOV genome is conserved between individuals, leading investigation into whether 




Figure 3.7: Intra-patient nucleotide variation across the EBOV genome. Shown for 
hospitalised fatalities (A) and survivors (B). The ratio of minor variants to coverage in a 



































































































When the intra-patient nucleotide variation of survivors and fatalities was compared 
more specifically, several coding changes were identified to be maintained in survivors 
but not as readily in their fatal counterparts. The viral polymerase (L protein) was 
examined in further detail as this is seen to be an area of high variability in survivors of 
EVD (Figure 3.7B). Here, the most common mutations found in the samples were 
compared between survivors and fatalities of EVD (Figure 3.8; identified by Carroll et 
al. 2015).  In most of the amino acid changes, the proportion was seen to be higher in 
hospitalised fatalities compared to survivors. Although the variation is higher in 
survivors, the specific mutations associated with amino acid changes (nonsynonymous 




Figure 3.8: Certain amino acid changes in L are more frequent in fatal cases of EVD. 
Multiple t tests were performed to compare hospitalised fatalities (H_F) and 
hospitalised survivors (H_S). * p < 0.05, *** p < 0.0005 with Bonferroni corrections for 
multiple comparisons. Here, counts of viral genomes with a specific amino acid change 
are normalised to the total number of samples in each group and presented as mean 































































To determine whether genetic variation of EBOV was confined to specific classes of 
nucleotide changes, all 12 nucleotide permutations (transitions and transversions) 
were determined for all patients, split by patient outcome (Figure 3.9). These data 
indicated that the A to G permutation was the most prevalent, with this effect being 
even more pronounced in hospitalised survivors. This permutation is suggestive of 
ADAR involvement. These enzyme binds readily to double-stranded (ds)RNA and are 




Figure 3.9: Intra-patient variation for all individual nucleotide permutations. Intra-
patient nucleotide variation for each of twelve possible permutations determined as a 
proportion of all minor variants. Where H_F are hospitalized fatalities (black) and H_S 

























































The was no differential expression of ADAR between fatalities and survivors, which is 
perhaps unsurprising due to the potential intrinsic nature of this protein. However, this 
could be due to the fact that ADAR exists in two isoforms: ADAR1 (interferon-
inducible) and ADAR2 (constitutively expressed in humans) (Samuel, 2011). Thus, 
transcriptomic data alone may not be able to accurately describe any difference in 
ADAR abundance.  
 
3.2.5 Comparison of EBOV variation in different body fluids 
One of the advantages of following up patients throughout their convalescence was 
the ability to sequence multiple samples from the same individual. Figure 3.10 shows a 
comparison of minor variants detected along the EBOV glycoprotein in a blood sample 
and semen sample from a convalescent patient. This gene was chosen due to the fact 
that it is the area of the highest risk of mutations. An interesting aspect of this 
comparison was that the same minor variants were not found in these different body 
compartments. However, this is not wholly surprising as these samples were taken 
seven days apart. The minor variants detected in the blood sample are more frequent 
but at a lower rate. However, once read depth is controlled for, the frequency of minor 
variants is not different between the two samples. Additionally, the ratio of 
synonymous to non-synonymous mutations is also not significantly different between 




Figure 3.10: Glycoprotein variation of blood and semen samples from the same 
individual. Instances of minor variants (MV) are shown across the EBOV glycoprotein 































































































































































































3.2.6 Identification of potential defective EBOV genomes 
In order to optimise further analytical approaches into the investigation of EBOV, 
samples from infected THP-1 cells were sequenced and investigated. These 
macrophage-like human cells are a model cell line for the in vitro study of EBOV 
activity due to the evidence suggesting that these viruses are capable of infecting 
macrophages (Geisbert et al., 2003). Differentiated THP-1 cells were infected with 
EBOV-Makona (H.sapiens-wt/GIN/2014/Makona-Gueckedou-C05) – a near-clinical 
isolate – in CL4 conditions. Following infection, cellular and viral RNA was extracted 24, 
48 and 72 h.p.i. These samples were sequenced using an Illumina HiSeq 2500. During 
mapping to EBOV using TopHat2 (Kim et al., 2013), a fusion search was enabled in 
order to search for truncated genomes and potential DIs. Increasing numbers of 
sequence reads mapped to the EBOV genome across the time course, including the 
untranslated regions (Figure 311A). Reads mapped to all viral genes in varying 
abundance with fewest corresponding to the L gene, as expected from the sequential 
nature of transcription in the Mononegavirales (Figure 3.11B, 3.11C). Somewhat 
surprisingly, more reads mapped to the glycoprotein (GP) region than any other gene. 
This could indicate that this region or the mRNA was more abundant in the cell. 
Alternatively, it could suggest increased stability of GP, or identify an enrichment 




Figure 3.11: Infected THP-1 cells accumulate virus over time, however, the viral 
profile appears to remain constant. After the RNA was extracted from infected cells 
and sequenced the proportion of reads mapping to EBOV increased over time, as 
calculated from the total reads (A). The coverage of viral genes stays relatively 




Searching for DIs in samples using RNA-seq was achieved by interrogating fusion 
events between disparate parts of the viral genome. Applying this approach to EBOV-
infected THP-1 cells identified 193, 711 and 1625 fusion events at 24, 48 and 72 h.p.i 
respectively (Table 3.2, Figure 3.12). This value is proportional once the increased 
number of reads mapping to EBOV are considered. In Figure 3.12 the section of the 
EBOV genome that has been deleted from the potential DI is shown as a horizontal 
line, with the depth of the colour indicating the level of support for this fusion event. 
These apparent discontinuities could have arisen during the reverse transcription step 
for sequencing or directly from the EBOV L protein. For this reason, the number of 
sequence reads supporting each fusion event was examined. Fisher’s exact statistic 
was used to create a stochastic threshold of 6 supportive reads, reasoning that rare 
events were less likely to be biologically significant. This greatly reduced the number of 
possibly relevant DIs from 2398 to 225. Of these, the ones most likely to be functioning 
as DIs are those appearing in each time point and increasing in abundance. This was 
down selected to nine serious candidates, with locations tending towards the 3’ end of 




Table 3.2: Detection of fusion events in EVOV-infected THP-1 cells. EBOV read depth is 
the number of reads mapping to the EBOV genome.  
 
24h 48h 72h 
EBOV read depth 958334 2273909 7649409 
Fusion events detected 193 711 1625 
Rate of fusion events      
(-Log[% fusion events]) 





Figure 3.12: Identification of potential defective genomes in Ebola-infected THP-1 
cells. Infected cells were harvested at 24 (A), 48 (B) and 72 (C) hours post infection and 
fusion events detected following Illumina RNA-sequencing. The colour of each deletion 
event depicts how frequently it was supported in the RNA-sequencing analysis, with 
high levels of support being light blue and lower levels of support being dark blue. The 
histograms on the right-hand side show the levels of support for all the fusion events at 
the corresponding time point.  
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After successfully identifying these fusion events in RNA extracted from 
experimentally-infected cell lines, the next step was use this pipeline to search for the 
same in clinical samples from the West African outbreak. Upon doing so, very few 
fusion events were found, even when a range of sample types were investigated (Table 
3.3, 3.4). Of those detected, very few were of substantial length, and likely to transmit 
any kind of advantage in speed of replication over the authentic virus. A number of 
fusion events were detected in blood and swab samples with no fusion events found in 
the urine or semen samples from convalescent patients. These samples generally had a 
lower viral load than the blood or swab samples we procured, therefore potentially 
not providing a sufficient coverage for fusion events to be detected. In the blood and 
swab samples, the vast majority of fusion events were suggestive of defective 
genomes that were shorter than the full EBOV genome by 100-300 nucleotides. 
Deletion events this small are unlikely to confer any kind of evolutionary benefit and 
therefore are of little interest. Some longer deletions were detected with the potential 
of being DIs. However, of these, only a smaller number would be considered to be 
“true” events due to the low rate of detection of these fusion events.  
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Table 3.3: Summary table of fusion events found in patient samples. Only blood 
samples with very high Ct values were considered to be appropriate for this analysis, 







Fusion events with 
at least 6 
supportive reads 
Swab 28 82 7 
Blood 44 18 0 




Table 3.4: Fusion events found in clinical samples. All of these samples are oral swabs 
from deaths in the community. These represent potential deletion DIs with length of 




















28 18035 18189 154 6 416 1.42180095 19.47 
74335 18025 18179 154 7 2944 0.23720773 14.1 
958 319 2510 2191 6 1323 0.45146727 16.18 
958 6293 6424 131 34 42951 0.07909736  
958 6305 6434 129 11 48642 0.02260909  
958 18025 18179 154 9 13568 0.06628858  






The identification of certain patient groups most at risk of a fatal outcome of EVD is 
critical in patient management. Here, and in other studies (Fitzpatrick et al., 2015; 
Vega et al., 2015; Kerber et al., 2016) and previous outbreaks (Towner et al., 2004), 
viral load is identified as being an indicator of patient outcome, as well as those with 
malaria as a co-infection (Figures 3.1, 3.3). In this study, age did not appear to impact 
prognosis, which opposes previous investigations (Fitzpatrick et al., 2015). The 
explanation for this could simply be that the vast majority of patient samples were 
taken from individuals aged between 20 and 60, thus older and younger individuals are 
not well represented. A higher proportion of women appeared to die in comparison to 
men, though this was not statistically significant. During the most recent EVD outbreak 
in the Democratic Republic of Congo, more women have seen to be infected than men 
(Nkengasong and Onyebujoh, 2018). This can potentially be attributed to the role of 
women in West Africa. Acting as caregivers, these individuals are at higher risk of 
infection and potentially wait longer before seeking the care or treatment they 
require, whilst still attending to other members of their family.  
 
This study demonstrates the importance of nucleotide diversity for EVD management. 
Next-generation sequencing allows the monitoring of EBOV evolution in the human 
host and demonstrates the magnitude of intra-patient variation. It is assumed that this 
intra-patient variation is, at least in part, driven by host defence mechanisms that can 
cause hyper-mutation of the RNA genome. Potential manipulation of the mutation 
frequency of EBOV during replication may provide a therapeutic avenue that could tip 
the balance between a fatal and non-fatal outcome.  
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Here, a higher viral diversity was observed in survivors of infection compared to 
fatalities. This could be indicative of a more effective immune response mounted by 
the survivors. A robust host immune response can lead to hypermutation in viruses as 
a method of immune evasion. This potentially leads to error catastrophe and a decline 
in the replication rate or pathogenicity of the virus.  
 
A to G transitions have been observed in a number of viral infections, including EBOV 
and other filoviruses (Zahn et al., 2007; Khrustalev et al., 2015; Whitmer et al., 2018). 
A pattern of substitution has been identified in an analysis of patient samples taken 
from seven months of the outbreak in Sierra Leone (Park et al., 2015). Thus, the 
increased frequency of A to G is common to different geographical isolates of the 
virus. It is notable that during the course of mouse adaptation, Marburg virus (MARV) 
underwent apparent ADAR editing, with clusters of A to G changes accumulating in the 
genomic RNA (Lofts et al., 2011; Qiu et al., 2014). Potential A to G transitions have also 
been observed in EBOV (Mayinga) and MARV RNA in cell culture experiments 
(Shabman et al., 2014). The A to G transition has also been observed, and therefore 
likely to contribute to the generation of escape mutants, from infected NHPs treated 
with a cocktail of three monoclonal antibodies targeted to the EBOV glycoprotein (Qui 
et al., 2016). This A to G transition is the most common among the patient samples 
when compared to a Makona isolate from very early in the outbreak (Figure 3.9). This 
is potentially due to the activity of ADARs – notably ADAR1, an interferon (IFN)-
inducible protein. The activity of ADAR1 has been observed to have potential anti- and 
pro-viral activity (Samuel, 2011).  
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The following up of patients throughout their convalescence has allowed the study of 
individuals experiencing persistent infections. The mechanism behind EVD persistence 
is not well understood (Varkey et al., 2015; Sissoko et al., 2017). The presence of DIs is 
one potential explanation, and these were readily identified in experimentally-infected 
THP-1 cells. These were seen to accumulate over time (Figure 3.12). Of those 
identified, the majority were only partially truncated and therefore unlikely to confer 
much of an evolutionary advantage over a wildtype virus. Studies on influenza have 
shown that the introduction of synthetically constructed DIs can dampen viral 
replication, thus demonstrating their potential use in a therapeutic setting (Dimmock 
et al., 2008). However, in this dataset very few were identified in patient samples. This 
is particularly troubling as samples from individuals with persistent infections were 
analysed. The explanation for this could be due to the lack of sufficient coverage in 
many patient samples, which is particularly notable when compared to the in vitro 
study, where high multiplicity of infection (MOI) can be used to infect cells. These high 
MOIs often do not reflect accurately a natural viral infection. Equally, this could be 
suggestive that these truncated genomes are simply an artefact of the replication of 
RNA viruses, and unlikely to be an important factor in EVD persistence in humans. A 
supporting factor of this is the fact that very little damage occurs in these persistently 
infected body compartments, suggesting that the virus has somehow been temporarily 
“turned off”.  
 
Here, Nanopore and Illumina RNA-seq could be closely compared. Unfortunately, the 
partially degraded condition of the RNA extracts proved to be a substantial issue when 
employing a MinION using Nanopore sequencing. There was a definite bias towards 
the 5’ end of the genome, which was expected, however this left the 3’ end almost 
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without coverage (Figure 3.4A). These reads are much longer when compared to the 
150 bp covered during Illumina sequencing. However, in this case, these long reads 
provide little advantage, as the overall coverage is much lower than samples 
sequenced using Illumina platforms. These shorter reads better allow issues of RNA 
quality to be overcome. No optimisation of this technique was performed and this 
MinION run was performed for cDNA sequencing following a PCR step, thus 
introducing a bias towards certain transcripts. Further bias was introduced by the fact 
that many of these reads begin at the same point along the EBOV genome. This could 
be due to the degradation of the sample that was sequenced. This bias is problematic 
when considering one of the aims of this project: the generation of a consensus 
genome. Direct RNA sequencing by Nanopore may return more informative results, 
and the error rate has dropped substantially over the last few years (Jain et al., 2016; 
Garalde et al., 2018). Additionally, the samples involved in this study were extracted in 
sub-optimal conditions at the ETC and stored for extended periods of time. Immediate 
sequencing following RNA extraction, and the use of an amplicon-based approach 
would maximise the data gained from Nanopore sequencing, especially when 
accommodating clinical samples, which could be of lower quality. The potential uses 
for this technology are plentiful and represent an exciting avenue for personalised 
medicine.  
 
3.3.1 Future work 
After the identification of a small number of potential DIs, the next step would be to 
assess their function in vitro in a number of EBOV-infected cell lines. This could give 
further indication as to whether these truncated genomes play an important role in 
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EBOV infection. Potentially, sequencing positive samples from convalescent patients at 












Chapter Four: Delineating the host 
response in Ebola virus disease and the 




4.1.1 Immune response to acute EVD 
Analysis of acute sufferers of EVD, including four patients who received intensive 
treatment at Emory University Hospital (GA, USA) during the 2013-2016 outbreak in 
West Africa, indicated that EBOV infection elicited a robust immune response (Hunt et 
al., 2015; McElroy et al., 2015). This challenged previous in vitro studies that suggested 
EBOV was able to effectively suppress the immune system through the activity of T 
lymphocytes, DCs and macrophages (Bosio et al., 2003; Mahanty et al., 2003; Basler 
and Amarasinghe, 2009). During the 2013-2016 outbreak, a feature of the host 
response to EVD was found to be an overwhelming of the immune system.  This was 
characterised by uncontrolled inflammation and lymphopenia (Ruibal et al., 2016).  
 
4.1.2 Predicting patient outcome of acute EVD 
The ability to predict patient outcome of infection based on changes in abundance of 
host factors could provide guidance for possible treatments and potentially uncover 
new therapeutic strategies for EVD. This is particularly important in outbreak 
situations, where clustering of patients requiring similar levels of care could be 
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critically important to effective delivery of the best possible care by healthcare 
workers. Several promising biomarkers were identified in a previous outbreak of SUDV 
(McElroy et al., 2014b, 2014a). However, currently, semi-quantitative viral load 
measurements by qRT-PCR (reported as a Ct value) are considered the gold standard 
for predicting EVD outcome. Viral load measurements for EBOV do correlate with 
outcome and therefore have some predictive ability (Carroll et al., 2015; Fitzpatrick et 
al., 2015). This has been implemented in the triage of patients receiving treatments, 
for example in Favipiravir trials during the 2013-2016 outbreak (Sissoko et al., 2016). 
However, using viral load as a predictor functions less well where Ct values are 
intermediate, i.e. between Ct 20 and 22. Here the outcome was approximately equal 
between survival and a fatal infection.  
 
4.1.3 Objectives and hypotheses 
In order to characterise the infection of EBOV-Makona in the 2013-2016 outbreak, 
deep sequencing was used to define the transcriptomic profile of blood taken from 
acute patients who either went on to survive or die from EVD. These samples were 
obtained from patients located in Guinea as described previously. During this 
outbreak, Guinea experienced the highest mortality rate for EBOV infection (Chapter 1, 
Figure 1.3). Thus, EVD patients in Guinea were optimal for correlating changes in the 
host response to outcome as there was little influence from intensive palliative and/or 
experimental care. This supportive care was utilised heavily to treat repatriated 
healthcare workers in high-income countries such as the USA and UK (Uyeki et al., 
2016). In these environments, 81.5% of patients who received supportive care survived 
while in contrast, the survival rate in Guinea was approximately 40%. However, this 
figure does not take into account the many asymptomatic cases that were identified 
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during this outbreak (Akerlund et al., 2015; Glynn et al., 2017). This fatality rate varied 
with patient age, with a higher proportion of older and younger individuals dying in 
this outbreak. This could, therefore, potentially be linked to the enrichment of specific 
pathways by individuals of a similar immunological maturity.   
 
The transcriptional signatures from acutely ill patients were compared to profiles 
obtained from convalescent patients who had recovered from EVD and were EBOV-
negative by qRT-PCR. Data was also obtained from healthy volunteers. This was 
performed in order to highlight differences in the host response to EVD at the time of 
acute infection with respect to patient outcome. These investigations could allow the 
development of prognostic tools, allowing patient outcome to be predicted accurately 







In order to identify changes in the host transcriptome of individuals infected with 
EBOV, the samples described in Chapter 5, Table 5.1 were utilised and down selected. 
Here, samples were selected that had a similar within-sample transcriptional profile 
(with an average correlation co-efficient above 0.8), thus reducing extreme variation 
within one patient group due to mRNA quality issues. Due to the diagnostic nature of 
the sample taking, these were from a mixture of Plasmodium spp. (the causative 
agents of malaria) negative and positive patients. Quality control criteria were used to 
identify and remove datasets from downstream analysis that showed evidence of 
having degraded mRNAs (expected from field sample collection). These criteria 
included the removal of samples that showed poor mapping to the human genome 
and low correlation values. From an initial set of 170 sequenced samples from 
individual patients, application of these selection criteria led us to discard 29 and 
analyse the data from 141 unique patients: hospitalised_survivors (n = 52) and 
hospitalised_fatalities (n = 89) (Table 4.1). The clinical outcome of these patients was 
unknown at the time of sample collection and subsequently recorded as they either 




Table 4.1: Summary of patients involved in this study. These have been split according 
to sample type and patient outcome. Here, patient age and EBOV Ct are described by 










N 89 52 16 24 
% Male 48.3 29.0 93.8 29.1 
Age 
(years) 
Range 2 mo – 77 10 mo – 68 18 – 40 1 - 70 
Mean 24.7 33.7 33.1 30.0 
EBOV Ct 
Range 12.1 – 26.6 15.8 – 31.6 NA 12.4 – 31.9 






4.3.1 Analysis of gene responses that differentiate patient outcome during EVD 
The transcriptomes from the blood of acutely ill EVD patients were analysed to identify 
mRNAs in both survivors and fatal cases that showed greater than 2-fold changes (at a 
false discovery rate [FDR] of 5%) in abundance compared to a convalescent control 
group. This control group provides a baseline for gene expression. Blood samples were 
taken from a group of 16 EBOV-negative individuals (by qRT-PCR) and convalescent for 
the disease (Table 3.1). During the 2013-2016 outbreak, amid the breakdown of the in-
country health-care system and the stigma of being associated with ETCs, acquiring 
samples from non-infected patients was challenging. These survivors represented a 
known EBOV-negative population that were also tested and confirmed to be 
Plasmodium-negative with no other overt clinical signs of an acute infection. A 
historical dataset was also used, which was obtained from the RNA-seq analysis of 
peripheral blood taken from healthy volunteers based in British Columbia (Canada) (n 
= 6) and thus would not have been exposed to EBOV or a range of other pathogens 
present in West Africa (Shin et al., 2014) (GEO Number GSE53655). Here, the 
transcriptomes of the convalescent group were compared to the healthy volunteers 
and not shown to be significantly different (Liu et al., 2017). Therefore, the 
convalescent control group was used as a comparison due to the likely similarities in 
host genomes.  
 
In the hospitalised survivor (H_S) group, transcripts from 437 genes were increased in 
abundance compared to the convalescent controls. This was increased to 1658 in the 
hospitalised fatalities (H_F), with 370 gene transcripts being shared between the two 
groups (Figure 4.1). Of these, many were transcripts of pro-inflammatory factors 
including CXCL10, CCL2, CCL8 and CXCL11, which were found to be of higher 
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abundance in fatalities compared to survivors. This phenomenon has also been 





Figure 4.1: Transcriptional responses to acute EVD during the 2013-2016 West 
African outbreak. Venn diagram depicting genes that are differentially expressed from 
fatalities to controls (red) and survivors to controls (green) (A). Radar diagram 
depicting pathways that are all upregulated in acute EVD sufferers verses controls, split 




There were distinctive differences in gene expression patterns when the 
transcriptomes from hospitalised fatalities were compared to those of hospitalised 
survivors. This was most strongly observed in genes associated with coagulation and 
acute phase signalling; with the top ten differentially expressed (DE) genes between 
hospitalised individuals and convalescent patients shown in Figure 4.2.  In these cases, 
the gene expression levels are higher in fatalities compared to survivors as well. Four 
of the DE genes associated with the clotting cascade were fibrinogen alpha chain (FGA, 
logFC +14), beta chain (FGB, logFC +13) and gamma chain (FGG, logFC +11). Later 
stages of EVD are often associated with coagulation disorders, with severe cases more 
likely to experience coagulopathy (Fletcher et al., 2014). Although overt haemorrhage 
was not often reported in this outbreak, those with abnormalities of the coagulation 
system were reported to experience more severe clinical symptoms (McElroy et al., 




Figure 4.2: Top differentially expressed genes comparing acute sufferers of EVD, 
separated by patient outcome. Here, log values of the normalised counts per million 
are shown, adjusted for feature length. Hospitalised survivors (H_S) are shown in green 





















































Interestingly, many of these top DE genes are involved in the same pathways of organ 
injury and abnormal function, as identified using IPA. Of these, the majority are 
increased in abundance in fatalities compared to survivors, and is enriched in 
hospitalised fatalities. This correlates well with reports of individuals suffering end-
stage EVD experiencing major organ dysfunction (Fletcher et al., 2014). In order to 
emphasise this, genes associated specifically with renal damage are highlighted with a 




Figure 4.3: Network of genes involved in organismal injury and abnormalities. Those 
genes that are upregulated in H_F are depicted in red, while downregulated genes 
appear in green. Genes outlined in pink are specifically associated with renal damage. 




In order to validate these findings, primers were designed for three of these top genes 
and qRT-PCR performed using a CFX96 (Bio-Rad) following amplification of cDNA using 
random hexamers. RNA extracts from the blood of six hospitalised survivors and six 
fatalities, not used in the previous DGE analysis, were tested for the presence of FGA, 
C7 and APOB. Here, the Ct values were normalised to RPL13A, a housekeeping gene 
that was seen to not be significantly different across patient groups following RNA-seq. 
As in the RNA-seq analysis, mRNA abundance of these genes was higher in hospitalised 
fatalities when compared to survivors, showing an increase in the abundance of FGA, 
C7 and APOB in fatal cases of EVD (Figure 4.4A). Additionally, a PCR array was 
performed covering “Human Inflammatory Cytokines and Receptors” (Qiagen) (Figure 
4.4B). This profiler array assesses the expression levels of 84 genes associated with the 
inflammatory immune response (see Appendix 7.3 for full list). A further 12 
independent samples were used to again compare the two patient groups. The PCR 
array includes a number of housekeeping genes in order to effectively normalise 
samples. These normalised values were then compared and the 84 potential genes of 
interest plotted against each other. Out of those genes, two were significantly 
upregulated in H_F compared to H_S: IL-8 and CXCL12. This fit well with the findings of 
the Illumina analysis. The expression levels of the vast majority of genes were not 
significantly differentially expressed between the two groups, however, this is likely 
due to the small sample size. In this analysis, CD40L was observed to be 




Figure 4.4: Comparison of hospitalised surivvors and fatalities using qRT-PCR 
techniques. Six hospitalised fatalities (H_F) and six hospitalised survivors (H_S) support 
the findings of the RNAseq analysis using targeted qRT-PCR of FGA, C7 and APOB (A). 
These were independent of the samples involved in the RNA-seq analysis. Values were 
normalised to housekeeping gene RPL13A. A profiler PCR array highlights the 
differential abundance of CXCL12, IL-8 and CD40L in these samples (B). Of the 84 genes 
associaed with the inflammatory response CXCL12 and IL-8 are shown to be 





























































4.3.2 Analysis of gene pathways differentiating patient outcome during EVD 
Pathway analysis using the KEGG database showed that hospitalisation of EVD patients 
was associated with a significant enrichment of genes from within the same signalling 
pathways, as compared with non-hospitalised patients. The most significantly 
represented included gene sets associated with interferon signalling, complement 
pathway, coagulation and cytokine-cytokine receptor interaction. Many interferon-
stimulated genes (ISGs) were strongly increased in abundance in all acute infection 
cases compared to the convalescent control group. This potential link between IFN 
expression and immunopathology has been noted in the 1995 Kikwit outbreak of EVD 
in the Democratic Republic of Congo (Villinger et al., 1999). In order to further 
investigate, these data were also analysed using Ingenuity Pathway Analysis (IPA, 
Qiagen Bioinformatics) to confirm the identity of signalling pathways associated with 
infection. This gave confidence to the KEGG analysis as many of the same immune 
pathways were identified, such as complement, IFN signalling and the coagulation 
cascade (Figure 4.1B). Further pathways were also identified that were indicative of a 
robust cytokine response – i.e. IL-6 and IL-8 signalling. In general, these pro-
inflammatory responses appear to be enriched in hospitalised fatalities when 
compared to survivors (Figure 4.1B). High levels of both IL-6 and IL-8 have been flagged 
previously as being associated with fatal cases of EVD (Hutchinson and Rollin, 2007; 
Wauquier et al., 2010).  
 
4.3.3 Immune cell profiles of EVD sufferers 
These observed changes in mRNA abundance in the blood of patients with varied 
prognoses could be due to the alteration of immune cell profiles. The altered 
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regulation and/or recruitment of specific immune cells could impact the transcriptomic 
signature of blood. Due to the constraints of this dataset, digital cell quantification 
(DCQ) was employed to identify which cell types may have been differentially 
abundant in hospitalised fatalities verses hospitalised survivors relative to the 
convalescent control group. This technique allows the immune cell profile to be 
predicted using only transcriptomic data via the implementation of a digital cell 
algorithm. The gene expression levels are utilised to forecast the potential abundance 
of cells types in each sample using FACS separating markers, which can then be 
compared across samples of a similar nature (Altboum et al., 2014). In both acutely ill 
groups the predicted immune cell profile involves a decrease in CD4+ T cells, which has 
been previously observed in NHPs (Reed et al., 2004). Conversely, CD8+ T cells are 
potentially increased in hospitalised survivors. The T cell response has been noted to 
be dysregulated in EVD (Ruibal et al., 2016). This DCQ also demonstrated a predicted 
fall in the circulating monocyte population, with this being most significant in fatal 
infections (Figure 4.5). This has been supported by flow cytometry on further samples 
from the 2013-2016 outbreak. This analysis indicated that CD14+ classic monocytes 
were in lowest abundance in individuals who suffered a fatal infection when compared 
to EVD survivors and those with acute malaria who tested negative for EBOV (Liu et al., 
2017). NK cells were also predicted to be more abundant in survivors of EVD (Figure 
4.5). This is consistent with the increase in mRNA abundance in hospitalised survivors 
of the NK markers IFN (4-fold higher than convalescent controls) and perforin (3-fold 
higher than controls).  
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Figure 4.5: Predicted immune cell abundance in acute sufferers of EVD compared to 
convalescent controls. Digital cell quantification performed and split into T cells (A), 
monocytes (B) and natural killer cells (C). As relative abundance to controls increases, 




4.3.4 The host response and the effect on patient outcome independent of viral load 
It is readily accepted that viral load is a critical factor in patient survival, supported by 
the results of this study (Chapter 3, Figure 3.1) where viral load was significantly 
different between survivors and fatalities.  Unsurprisingly, the above analyses involved 
patients with a diverse range of viral load. In order to confirm that the host response 
played an important role in patient outcome unconnected to viral load, an 
independent dataset was procured. This consisted of a group of 20 individuals (all 
testing negative for Plasmodium spp.) with an EBOV Ct value between 20 and 22, ten 
of whom died following hospitalisation whilst ten survived. This Ct range was chosen 
because it is not a reliable predictor of patient outcome, with a fatality rate of 
approximately 50%.  
 
From the perspective of biological understanding of the disease, this allowed 
investigation into whether this differential expression of host factors was potentially 
independent of viral load. Upon mapping to the human genome and multidimensional 
scaling (MDS), these samples did not appear to cluster effectively according to their 
outcome (Figure 4.6). Differential gene expression analysis was performed using the 
transcriptomes of the samples in each group of patients. This identified the 
enrichment of very similar transcript abundance to that described in the original n = 
141 analysis on the H_F and H_S patient groups.  This suggests that the host response 
(at least at the transcript level in the blood) was mainly independent of viral load, with 
FGA, FGL1, ALB and FGB all being among the top ten differentially expressed genes 
(Table 4.2).  
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Figure 4.6: Principle component analysis (PCA) for ten hospitalised survivors (green) 
and fatalities (red) with comparable viral load. The PCA was performed using the 
feature count values following alignment to the human genome and is based on the 




Table 4.2: Top ten differentially expressed genes between hospitalised survivors (n = 
10) and fatalities (n = 10) with comparable viral load. Those among the top ten DE 
genes in both the n = 20 and n = 138 studies are shown in bold.  
Gene name Fold change H_F/H_S 
Fibrinogen alpha chain (FGA) 2268.032377 
C-reactive protein (CRP) 1325.288791 
Fibrinogen like 1 (FGL1) 
1315.405824 
Albumin (ALB) 456.5393164 
Fibrinogen beta chain (FGB) 450.5231655 
Ceruloplasmin (CP) 349.1619036 
Complement C9 (C9) 147.4703656 
cAMP responsive element binding 
protein 3 like 3 (CREB3L3) 
51.74968168 







4.3.5 The effect of patient age on host response 
Although not identified in our dataset as being a significant factor (Chapter 3, Figure 
3.3A), previous studies of EVD have shown age to be a determinant of survival (Sadek 
et al., 1999; McElroy et al., 2014a). In EVD outbreaks, individuals under the age of 5 
and over the age of 45 appear to be at higher risk of fatality (Vega et al., 2015; Li et al., 
2016). This is not an uncommon occurrence, with similar trends seen in HIV (Martin et 
al., 1995; Darby et al., 1996), CMV (Pawelec et al., 2012) and Dengue (Guzman et al., 
2002), among others. It is possible that this association was not identified in this 
dataset due to the vast majority of patients being between the ages of 5 and 45. 
Despite this, investigations into which pathways are enriched in each age group was 
performed in order to potentially explain this phenomenon. 
 
Patients were split according to their immunological age and outcome and KEGG 
analysis performed. A number of pathways were registered as being enriched in the 5-
45 age group when compared to those under 4 and above 45, with a selection shown 
in Table 4.2. In the <4 group, the top pathways that are enriched in H_F compared to 
H_S are not observed to be differentially expressed. This makes sense as the 
haemostatic system is very different in infancy and adulthood (Andrew et al., 1992). 
Therefore, the issues delineating fatal and non-fatal infections are different from those 
in the general population. Furthermore, although the pathways of complement, 
coagulation and cytokine interactions separated patients according to their outcome in 
individuals over 45, specific inflammatory responses, namely TNF- and NF-kB-signalling 
and chemokine production, were less important (Figure 4.7). This could be due to 
immunosenescence, with these pathways not functioning as well in an ageing 
population. In elderly humans, many facets of the immune response become 
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compromised, including the activity of neutrophils and NK cells (reviewed in Gomez et 
al., 2008).   
 
In the youngest age group (< 4 years), the malaria pathway was enriched in 
hospitalised fatalities, which gives support to this analysis as these individuals are at 
the highest risk of contracting the disease (Appendix 7.2). However, very few pathways 
were enriched in this age group. This is potentially due to the fact that it did not 
include many individuals. The absence of such immune response pathways must be 
considered with the small group size. In the eldest age group (> 45 years) some 
enriched pathways were associated with the inflammatory response, while others 
included those associated with cancer. This is unsurprising as this age group is at the 




Figure 4.7: GO plot showing the KEGG pathways that are upregulated in hospitalised fatalities in each age group when compared to survivors. The 
full tables can be found in Appendix 7.3. 
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4.3.6 Prognostic capabilities of differentiated gene responses between patient groups 
One application for differential gene expression analysis could be to identify suitable 
biomarkers for predicting the outcome of infection in individual patients. This could 
allow an improvement in triage, more effective allocation of treatment modalities and 
a logistical advantage to healthcare workers. This prediction would need to be 
achieved via the results of Nanopore sequencing or qRT-PCR in order to be completed 
rapidly enough to be beneficial.  
 
As EBOV diagnosis is achieved via qRT-PCR, the most logical step appeared to be to 
pick a number of host genes and perform this semi-quantitative measurement on 
them. Here, VCAM1, ISG15 and TUBG1 were chosen due to their importance in the 
immune response and differential expression following the Illumina analysis (top 20 
shown in Appendix 7.1). These qRT-PCR experiments were performed on a set of RNA 
extracts from whole blood of patients from the 2013-2016 EVD outbreak that were 
independent from those used in the previous analyses. This group comprised of 19 
survivors, 20 fatalities and 6 uninfected controls (European individuals who would 
have never come into contact with the virus). The expression of VCAM1 and ISG15 
were seen to be significantly higher in the H_F compared to H_S (Figure 4.8). There 
was not a significant difference between TUBG1 expression, however, this was 
included for completeness.  
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Figure 4.8: Differential abundance of target genes in an independent set of H_S and 






































































in green and H_F in red. Mann-Whitney test performed to compare groups. **** 




This allowed a linear discriminant analysis (LDA) to be performed, which takes 
quantitative information to differentiate binary groups. In this case, the differentiation 
of hospitalised survivors and fatalities using the calculated copy number of these 
selected genes as well as the viral load (Figure 4.9). This analysis calculates correlation 
coefficients for each factor and how they separate patients (Figure 4.9A). As expected, 
viral load is very effective in separating patient groups. This LDA was performed using 
a randomly selected training set of 60% of the tested samples (24 samples) and tested 
on the remaining 40% (15 samples). A linear model was able to successfully separate 
samples according to these factors (Figure 4.9B), and these were seen to be predicting 
survival with an accuracy of 100% even when EBOV Ct was used along with any single 
host gene classifier, despite this difference not being significant in TUBG1 according to 
the qRT-PCR. This is illustrated thoroughly in the separation achieved in the partition 
plot (Figure 4.9C). In this plot, each coloured area denotes a classification (in this case 
patient prognosis), thus the effective separation of these colours determines that 
using these two variables can effectively separate data into the correct groups. For 
example, the top left panel illustrates the effective separation achieved when using 
EBOV Ct and VCAM expression to predict patient outcome. However, when EBOV Ct is 
not included, this separation is much more difficult to achieve, as illustrated by the 
bottom right panel (Figure 4.9C). Here, TUBG1 and ISG15 expression cannot effectively 
separate samples into groups. These samples had EBOV Ct values that could be used to 
predict patient outcome, so the model was reconstructed without including EBOV Ct 
and an LDA performed again (Figure 4.10). Upon the development of this model, the 
training dataset was able to predict patient outcome with 83%, which increased to 
90% using the testing dataset. This could suggest that using a multiplex PCR approach, 
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healthcare workers would be able to accurately predict patient outcome, even in cases 








Figure 4.9: Linear discriminant analysis comparing hospitalised survivors, 
hospitalised fatalities and controls. Based on the copy numbers for three host genes: 
VCAM, ISG15, TUBG1 and Ct values for EBOV (denoted Ct). Correlation coefficients 




Figure 4.10: Linear discriminant analysis in the absence of viral load. Based on the 
copy number for three host genes: VCAM, ISG15, TUBG1. Correlation coefficients 





4.3.7 Using Nanopore sequencing to study the host response 
Illumina sequencing of our samples provided a substantial quantity of data and many 
interesting avenues to study. The development of a prognostic tool creates the 
potential for the influence of patient management. Patients with similar levels of care 
could be housed together, thus improving the efficiency of the healthcare workers. A 
challenge associated with Illumina sequencing is that the analysis takes several weeks 
and can only be performed by individuals who have undergone extensive training. 
Following this period, acutely ill individuals would no longer be in the ETC. Nanopore 
sequencing, which was employed in the field at EMLab sites for phylogenetic purposes, 
can be performed rapidly and with minimal training. Long reads are accessible within 
just 15 minutes. This provides the potential for real-time sequencing and mapping to 
the human genome, with the results being potentially used to inform patient 
treatment (for example the provision of αIFNs etc.) or to allocate limited resources to 
patients.  
 
Six RNA samples extracted from the whole blood of three survivors and three fatalities, 
were sequenced using a MinION (Nanopore Technologies, Oxford) and the reads 
mapped to the human genome. The samples did appear to cluster successfully 
according to patient outcome following PCA analysis (Figure 4.11A). Despite this, the 
number of passed reads collected from Nanopore sequencing was much lower than 
that using Illumina sequencing. However, many of the same genes were upregulated in 
the fatalities compared to the survivors as shown by the Illumina data (Figure 4.11B).  
 
Despite these similarities in general trends, the top DE genes following Nanopore 
sequencing were not necessarily as expected.  Genes that had not previously been 
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highlighted as being associated with EVD within the aforementioned Illumina study or 
elsewhere were identified. However, at a systems biology level there did appear to be 
an enrichment of particular pathways associated with the immune response. 
Additionally, a number of specific genes with an overwhelming pro-inflammatory 
response are seen to be upregulated in H_F compared to H_S. This included ISG15, 
which has been shown to have predictive ability in EVD patients.  
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Figure 4.11: Differentially expressed genes in fatalities compared to survivors of EVD 
following Nanopore sequencing. Following mapping to the human genome, a PCA was 
performed to show grouping of samples (A), with six genes associated with a pro-
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inflammatory response shown to upregulated in fatalities compared to survivors (B). 
Three H_F and three H_S samples were sequenced on a MinION platform and their 
levels of gene expression compared using DESeq2.  
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4.3.8 A comparison of experimentally infected samples to naturally infected humans 
Previous studies have highlighted the similarity between the response of humans and 
NHPs to EVD (Geisbert et al., 2000; Hensley et al., 2012). However, due to the cost 
associated with working with NHPs, other mammalian models have been developed. 
One such model is that of the guinea pig.  Guinea pigs are initially asymptomatic to 
EBOV infection, but this alters as the virus adapts to the host upon sequential passage 
(Volchkov et al., 2000; Dowall et al., 2014). Following adaptation, EBOV becomes more 
virulent and produces fatal infections coupled with an extensive immune response 
with many similarities to that seen in humans (Connolly et al., 1999; Padilla-Carlin et 
al., 2008; Nakayama and Saijo, 2013).  
 
Previously, colleagues had performed infection experiments with this model organism 
in containment level (CL) 4 conditions at Porton Down (Public Health England) (Dowall 
et al., 2014). Here, RNA was extracted from the pooled spleens of six infected guinea 
pigs. This allowed a comparison between these experimentally infected guinea pigs 
and naturally infected humans from the West African outbreak. Though there is a 
difference in terms of the source material, general trends in cytokine activity could still 
be observed.  
 
Dowall et al. (2014) infected guinea pigs with EBOV and used a homogenate prepared 
from the spleens of infected subjects to infect the subsequent group. This continued 
until an increase in pathogenicity was demonstrated. At each stage, the initial viral 
concentration was kept constant. From these passages, RNA was extracted and 
sequenced using a MiSeq Illumina platform. This allowed the analysis of both the host 
response as well as the virus itself. Following transcriptomic analysis, a number of 
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critical immune response markers were seen to elevate across this time (Figure 4.12). 
These include a number of genes associated with interferon (IFN) signalling. 
 
IFN stimulated gene (ISG)15 and IFN-induced protein with tetratricopeptide repeats 
(IFIT)5 have been previously shown to be significantly upregulated in acute EVD 
patients in comparison to a convalescent control group (Caballero et al., 2016; Liu et 
al., 2017). In mouse models, the upregulation of ISG15 has been observed to have 
protective qualities (Malakhova and Zhang, 2008; Okumura et al., 2008). However, in 
the guinea pig experimental model the upregulation of ISG15 increases through 
sequential passages and along with the fatality rate. IL-18 is an inducing factor of IFN 
and has been previously found to be upregulated in infected monkeys (Hensley et al., 
2012). Together, these data suggest that IFN signalling plays a critical role in EBOV 
pathogenicity in guinea pigs as well as other mammals.   
 
A number of cytokines and chemokines were also observed to be expressed in greater 
abundance in later passages. This follows the pattern observed in the human data as 
the abundance of pro-inflammatory cytokines increases alongside severity of infection. 
The abundance of these cytokines can lead to a cytokine storm and is associated with 
severe immunopathology (Zampieri et al., 2007).  For instance, CCL2 is a chemokine 
capable of recruiting immune cells such as monocytes and dendritic cells (Conrady et 
al., 2013). CCL2 and CXCL10 have been implicated as having a key role in pulmonary 
immunopathology following respiratory syncytial virus (RSV) infection (Culley et al., 
2006). Tumor necrosis factor (TNF) makes up an important part of the acute phase 
response, a pathway also highlighted to be enriched in acute EVD sufferers and 
associated fatal infections (Baize et al., 1999; Hensley et al., 2012; Liu et al., 2017). 
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CXCL11 is a recruiter of activated T lymphocytes, which has been shown to be 
upregulated in EBOV-infected macaques (Caballero et al., 2016). In the guinea pig 
model, there were distinct differences in transcriptomic profiles between passages, 
with a number of genes being differentially expressed between passage 2 and passage 
5. Passage 1 was not used as a baseline as the initial injection likely had a substantial 
effect on the immune response. This potentially explains the pattern observed in 




Figure 4.12: Gene expression levels of immune response markers across passages. 
Each data point shows the value from sequencing a pooled sample from four guinea 
pigs in each passage. Read depth represents the fragments per kilobase of transcript 
per million mapped reads (FKPM). 
  


















































The top DE genes (Figure 4.13) show a considerable change in mRNA abundance, 
showing the significant effect that EBOV infection imparted on subjects. These genes 
have all been demonstrated to play significant roles in viral infections. Previous 
experimental data suggested that viral protein VP24 was able to inhibit IFN signalling 
via the blocking of STAT1 (Reid et al., 2006; Zhang et al., 2012), however this is not 
reflected in experimentally infected animals or natural infections (Caballero et al., 
2016; Liu et al., 2017). Here, STAT1 is highly upregulated in later passages. HSPA8 
expression is upregulated in cases of cellular stress including infection and 
inflammation as exhibited by Tsuboi et al. (1994), including in response to Epstein-Barr 
virus (HHV4) (Stricher et al., 2013). RIPK2 appears to play a key role in a number of 
viral infections, including apoptosis in dengue infection (Morchang et al., 2011) and 





Figure 4.13: Top differentially expressed genes from passage 2 to passage 5 in EBOV-
infected guinea pigs. Mean fold change (log2) is shown as a proportion of FKPM 













































Once again, IPA was employed to identify certain pathways associated with the final 
passage. These data predicted the enrichment of specific signalling pathways 
associated with the immune response (Figure 4.14). NF-kB has often been implicated 
in viral infections due to its role in immunity and apoptosis. NF-kB has been associated 
with IL-18 and NR3C1 expression in hepatitis C infections (Capone et al., 2014). IL-8 
signalling was also identified to be increased in later passages, as well as in fatal 
human infections (Liu et al., 2017). This enrichment of neutrophil and granulocyte 
chemotaxis could be responsible for much of the immunopathology experienced by 
the guinea pigs in this study. A higher proportion of subjects in later passages died in 
comparison to earlier ones, so this finding parallels what has been seen in outbreaks.  
 
JAK/STAT signalling was highlighted as being enriched in passage 5, which is not 
surprising as STAT1 was one of the top differentially expressed genes in these samples 
(Figure 4.13). The activity of IFN can trigger the JAK/STAT signalling cascade, which in 
turn leads to the transcription of a number of ISGs (as reviewed by Fensterl and Sen, 
2009). Of the top differentially enriched pathways, the vast majority were upregulated 





Figure 4.14: Top canonical pathways differentially enriched from passage 2 to 




Following the pathway analysis, a DCQ was performed using ImmQuant, due to the 
analysis of samples from rodents (Frishberg et al., 2016). This enabled a comparison to 
be made with the one performed using human data (Figure 4.5) and allowed an 
immune cell profile to be predicted. This was performed as cellular abundance can 
have a dramatic influence on the transcriptomic profile. Here, a number of key 
immune cell types can be seen to increase in response to infection (Figure 4.15). 
Notably, there is increase in neutrophils across passages, which supports the detection 
of the IL-8 pathway as being enriched in Figure 4.14. Additionally, the gradual increase 
of mature CD56+CD16+CD3- NK cells shows an attempt to control infection. NK cells 
expressing CD56 and CD16 usually account for the majority of circulating NK cells and 
have cytotoxic functions, being significant producers of a number of proinflammatory 
cytokines (Cooper et al., 2001). NK cells have been implicated as playing an important 
role in EBOV infection in humans (Cimini et al., 2017; Liu et al., 2017).  
 
The steady increase in the presence of eosinophils was likely due to the formation of 
eosinophilic intracytoplasmic inclusions, which have been noted previously in livers of 
EBOV-infected cynomolgus monkeys (Geisbert, et al., 2003). These inclusion bodies 
represent sites of viral replication, formed from aggregates of viral proteins. The 
increase of eosinophils alongside that of viral load is commonly observed in a number 
of other viral infections including rabies (Lahaye et al., 2009).  
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Figure 4.15: Predicted immune cell profile of passages 3, 4 and 5 in comparison to the 
cell abundance of passage 2. Heatmap constructed following digital cell quantification, 
with the colour legend representing the relative abundance (log2) of each cell type 
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Studying EVD carries a number of challenges, not only due to its requirement for high-
containment laboratories, but also due to the fact that it affects countries in low-
resource settings, negatively impacting the ability of healthcare workers to effectively 
monitor patients and provide care. There are debates as to the best way to study 
EBOV and its effects. Several appropriate animal models exist; however, these do not 
always mirror the human course of infection (Safronetz et al., 2013). In this study, 
diagnostic testing for EBOV has provided RNA extracts from the whole blood of 
infected individuals and allowed investigation into the host response to infection. 
These findings highlight the insights that transcriptomic analysis can provide into 
improving clinical management of disease.  
 
The ISG pathway was observed to be heavily enriched in this cohort of EVD patients 
compared to controls. This finding is noteworthy due to previous associations of the 
ability of EBOV to dampen the IFN response (Basler et al., 2000; Basler and 
Amarasinghe, 2009). More recently, IFNβ responses have been found in expatriated 
EVD patients with moderate disease (McElroy et al., 2016), which studies in NHPs have 
postulated as potentially providing some protection against EBOV and Marburg virus 
(MARV) (Smith et al., 2013). In our Guinean cohort, the substantial increase of IFN 
activity in severe, eventually fatal infections may suggest the opposite. Certainly, a link 
between the activation of IFN-like pathways and survival cannot be established in the 
absence of additional palliative care as these patients tended to have a poorer 
prognosis. This is mirrored in NHPs given a lethal challenge of EBOV, where an 
 145 
uncontrolled IFN response may decrease an individual’s chance of survival (Rubins et 
al., 2007). Potential mechanisms for this include the formation of an uncontrolled 
cytokine storm as well as lymphocyte apoptosis (Hensley et al., 2012). IFN signalling 
has been linked to immunopathology in many viral infections, with the uncontrolled 
production of pro-inflammatory cytokines often correlating with disease severity. 
Influenza and respiratory syncytial virus are examples of this (Ostler et al., 2002; Jong 
et al., 2006). This cytokine-mediated immunopathology is readily reproducible in 
animal models, and these have been critical in furthering our knowledge of EBOV 
pathogenesis. Here, a robust immune response was observed in guinea pigs following 
EBOV infection and the adaptation of the virus to the host. This mirrored the human 
response well in terms of transcriptomic analysis of samples from the 2013-2016 
outbreak in West Africa. This is also reflected at an immune pathway level, with IFN-
associated pathways and those involved in inflammation being upregulated in later 
passages, when guinea pigs were experiencing higher fatality rates and increased viral 
load. DCQ analysis indicated an upregulation of NK cells and eosinophils, suggesting 
the importance of cytotoxic immune cells as well as the formation of eosinophilic 
intracytoplasmic inclusions in the spleens of infected guinea pigs. However, this is 
based on the sequencing of the pooled spleens of infected guinea pigs and so caution 
should be taken when comparing these samples. Furthermore, the pooling of these 
organs means that only the overall trend can be investigated. Therefore, some of the 
individual effects observed in each organism may have been masked. 
 
Another majorly enriched pathway was that of complement and the coagulation 
cascade, also found following the KEGG analysis, with fibrin deposition having been 
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previously associated with EBOV infection (Geisbert et al., 2003; Feldmann and 
Geisbert, 2011). However, much of the mRNAs associated with such genes are not 
readily found in the blood and considered to be liver-specific. In this outbreak, fewer 
individuals with EVD were observed to be suffering from haemorrhagic symptoms 
(Chertow et al., 2014), but liver and kidney damage was very common in the later 
stages of disease. This aberrant organ function was confirmed by looking at levels of 
aspartate transaminase (AST) and alanine transaminase (ALT) (Lyon et al., 2014; 
Schieffelin et al., 2014). Therefore, the identification of these mRNAs could be due to 
leakage of hepatic mRNAs into the blood. This would explain why these transcripts 
were more abundant in the blood of those who subsequently succumbed to infection.  
 
One of the limitations of this study is that any conclusions made can only be applied to 
the blood transcriptome of individuals with EVD. Therefore, a critical finding of this 
study was the similarities to protein abundance in cytokine and chemokine expression, 
both in this outbreak (Ruibal et al., 2016) and several previous in Gabon and Republic 
of Congo (Wauquier et al., 2010). This is a particularly pertinent consideration in 
analysing outputs of certain tools employed in this study, for example the DCQ. This 
presents a prediction of the immune cell profile based on gene expression data. 
However, many of the genes this is based on can be influenced by other factors and 
therefore should be interpreted carefully. One such example is the predicted increase 
in NK cells due to the presence of IFN (Figure 4.5). Although a known marker for NK 
cell activity, this cytokine can also demonstrate the activity of other cell types and 
associated pathways.  
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Here, major differences are observed between the transcriptome taken from 
hospitalised survivors when compared to their fatal counterparts. The explanation for 
this could be due to the differential activation of gene transcription but also the 
potential difference in immune cell profiles between these groups. Cytokines and 
chemokines lead to cell recruitment, so the difference in immune response will directly 
affect the infiltration of specific cell types. Such differences were predicted using a 
DCQ analysis, which noted a higher proportion of monocytes in hospitalised survivors. 
This finding was validated using FACS on similar patient samples (Liu et al., 2017), 
providing confidence in the accuracy of the DCQ. NK cells were highlighted as also 
being more abundant in hospitalised survivors, which is unsurprising as these cells 
have been suggested to provide a protective effect in EVD in experimentally infected 
mice (Williams et al., 2015). This priming of the innate immune system may therefore 
be critical in successfully fighting an EBOV infection.   
 
These differences allowed certain genes to be selected for further qRT-PCR and an LDA 
performed by taking this quantitative information and using it to separate H_S and 
H_F. In this case, it was used to effectively predict patient outcome and therefore has 
the potential to be included in the formation of a prognostic tool in the form of a 
multiplex PCR. During the construction of this LDA, age was initially included in the 
analysis, however, this had no beneficial impact and was therefore removed. qRT-PCR 
is already performed to confirm the presence of EBOV, so the development of an 
effective multiplex PCR would not delay any provision of diagnosis. When EBOV Ct was 
included in the LDA, even with a sample size of only 20, this information, along with 
one or more host genes, allowed patient outcome to be correctly predicted in every 
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case. Even when EBOV Ct was not included in the LDA, patient outcome was able to be 
predicted with an accuracy of 90% in the testing dataset, representing 40% of the 
independent samples. This could provide useful information to healthcare 
professionals and inform clinical management of patients, which is particularly 
important in low-resource settings. This method could be particularly valuable in cases 
where viral load is not an effective indicator of patient outcome, including herpes 
simplex encephalitis (HSE), caused by herpes simplex virus (HSV) (Saraya et al., 2016). 
HSE is particularly notable as it is responsible for a large proportion of the global cases 
of viral encephalitis and has high rates of mortality (Solomon et al., 2012).   
 
In a future outbreak, the accuracy of this model is likely to increase over time as 
increasing data points are added. However, it should be noted that it is possible that 
the success of this model may not extrapolate to further samples. Testing on a blinded 
sample set would be an effective test of the model, where the outcome of the patients 
is unknown. In these cases, patient information such as age and malaria status could 
also be included to aid in the accuracy of outcome prediction.  
 
The other option for the formation of a prognostic tool would be to use Nanopore 
sequencing at the ETC. This real-time sequencing method was performed for 
phylogenetic purposes during the 2013-2016 outbreak, showing the ease of 
implementing such methodology, even in such low-resource settings (Quick et al., 
2016). However, in this study, a transcriptomic approach was taken to study the RNA 
extracts from EVD patients. Successful reads were mapped to the human genome 
using BWA-MEM. Here, the quality of the RNA sample was found to be extremely 
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important in the success of each MinION run. Lower quality RNA extracts yielded 
substantially fewer reads than those of higher quality. This was much less dramatic 
using Illumina as a sequencing method. The RNA used with this method had been 
stored for over a year at -80C, with few freeze-thaw events. Although the conditions 
were kept optimal for RNA storage, some degradation is inevitable (Auer et al., 2014). 
It was found that upon sequencing of fresh extracts from clinical samples, using 
Nanopore sequencing with the same kit produced increased read length and quantity. 
Additionally, this approach included a PCR step, introducing a potential bias towards 
shorter transcripts.  
 
However, Nanopore platforms have been used effectively to sequence clinical 
samples, thus could be implemented for use in clinical settings if the process were to 
be refined. The general trends observed between H_F and H_S were found to be very 
similar when comparing analysis of Illumina and Nanopore data. For the moment, 
Nanopore sequencing represents a significantly more expensive method of 
determining patient prognosis, therefore supporting the use of qRT-PCR of targeted 
genes. The identification of enriched pathways in the hospitalised survivors at different 
immunological ages could also inform clinical practice and be a step forward in 
personalised treatment of EVD. The differential enrichment of certain pathways in 
different age groups also points towards a benefit to a more personalised approach to 
treating EVD.  
 
Delving further into the genetics of patients with EVD could also delineate some of the 
factors influencing patient prognosis. This is challenging given the transcriptomic data 
acquired in this study. However, one option would be to use software capable of 
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predicting HLA types from such data in order to compare patient groups. Additionally, 
a SNP analysis of the human genome of this dataset could help to better understand 




Chapter 5:  The impact of co-infections on 




5.1.1 Activation of the interferon response during EVD 
The 2013-2016 outbreak in West Africa has provided many insights into EBOV 
pathology and EVD. The utilisation of next-generation sequencing (NGS) during this 
outbreak has allowed investigation into the virus itself as well as the antiviral 
responses of hosts. One observation that has been highlighted is the difference 
between the host response that we observe in experimental in vitro infections and the 
response of patients, particularly in the acute immune response. One example of this 
is the role that interferons (IFNs) and interferon-stimulated genes (ISGs) play in the 
host response. These were long thought to be successfully supressed by viral genes 
VP35 and VP24 (Basler et al., 2000; Basler and Amarasinghe, 2009), however; this is 
not supported by studies of infected patients (Caballero et al., 2016; Liu et al., 2017). 
Real-life infections represent a much more complex system than that of in vitro 
infections. One stark difference is the underlying burden of disease that we observe in 
many of the countries where Ebola outbreaks have occurred. This could be a pivotal 
factor in the immune response and why we don’t see this IFN response during 
experimental infections. IFNs are cytokines grouped into three classes: types I, II and 
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III. Type I IFNs (most importantly IFN and ) are secreted following detection of viral 
particles. IFN, belonging to type II, is secreted by T lymphocytes and natural killer (NK) 
cells following their activation. These IFNs act to create an antiviral state, playing a key 
role in the host immune response. Type III IFNs can also support the formation of an 
antiviral state, but their distribution is more limited due to production by restricted 
cell types (Randall and Goodbourn, 2008).  
 
5.1.2 Plasmodium falciparum as a co-infection 
In Guinea, where the majority of our samples originate, the incidence of malaria is high 
(367.8 cases per 1000 population in 2017) and 100% of the population are at risk of 
exposure (WHO, 2018). The protozoan parasite species responsible for these cases is 
Plasmodium falciparum. Guinea is considered to be one of the poorest countries in 
West Africa, with only half of the population having access to public healthcare 
services. This can act as a barometer for how substantial the burden of disease could 
be among the population. Deaths due to malaria and lower respiratory infections are 
responsible for almost a quarter of all deaths in Guinea (12.5% and 10% respectively) 
and malaria is the biggest killer of those under the age of five (WHO, 2018). Malaria as 
a co-infection with EVD has been implicated in influencing patient outcome (O’Shea et 
al., 2016; Rosenke et al., 2016). However, the direction that this takes is not 
transparent.  
 
5.1.3 Viral and bacterial co-infections 
There is a plethora of other co-infections that have been observed to impact patient 
outcome. Lauck et al. (2014) found that co-infection of Zaire ebolavirus (EBOV) with GB 
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virus C (GBV-C, formerly hepatitis G virus) was associated with patient survival. Human 
herpesvirus 4 (HHV4, formerly Epstein-Barr Virus) is a member of the Herpesvirus 
family and has a high incidence in developing countries (Chakraborty et al., 2010; 
González Saldaña et al., 2012). In a healthy individual this virus can coexist with the 
host, but as an opportunistic infection it can have deleterious effects. Reactivation of 
the virus has been observed in individuals with EVD following the impairment of the 
host immune response (Agrati et al., 2016). Throughout the course of EVD 
gastrointestinal involvement is very common. This can lead to the translocation of 
pathogens from one body compartment to another (Kreuels et al., 2014; Wolf et al., 
2015). Incidences of bacterial septicaemia have been noted in cases of EVD (Kreuels et 
al., 2014), but not fully investigated due to the nature of an outbreak situation of a 
viral agent. Suspected bacterial infections are usually treated following clinical rather 
than laboratory diagnosis (Hunt et al., 2015).  
 
5.1.4 The effect of age on co-infections 
The link between patient age and their probability of surviving EVD has been 
documented previously, with those who are very young or very old experiencing 
higher fatality rates (Sadek et al., 1999; WHO, 2014). Older EVD patients are at greater 
risk due to immunosenescence, defined as the exhaustion of the immune response. 
Persistent infections cause the dysregulation of many parts of the immune response, 
with notable differences occurring in the T cell compartment as well as the innate 
response (as reviewed by Fülöp, Larbi, & Pawelec, 2013 and Solana et al., 2012 
respectively). This effect is particularly notable in populations experiencing a 
substantial burden of disease. Due to this mechanism, this effect is also observed in 
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other viral and bacterial infections. Additionally, the presence of certain co-infections 
would be expected to be more prominent in certain age groups. This is important as it 
further supports the functionality and validity of our analysis pipeline.  
 
5.1.5 Identification of potential co-infections 
In this study, Illumina RNA-sequencing was used to identify the presence of 
microorganism-specific nucleic acids in RNA extracts of whole blood representing 
potential co-infections. This has been performed in previous studies using target 
independent sequencing techniques for respiratory and haemorrhagic viruses as well 
as other potential pathogens (Fischer et al., 2015; Thorburn et al., 2015; Dinçer et al., 
2017; Ramesh et al., 2018). In a study of viral respiratory pathogens, a cut-off Ct value 
of 32 was posited as providing enough information for viral identification by next-
generation sequencing (Thorburn et al., 2015). This unbiased approach allows the 
identification of viral, bacterial, fungal and parasitic sequences in diagnostic samples.   
 
At the Ebola Treatment Centre (ETC), Plasmodium spp. were tested for via an RDT 
(BinaxNOW Malaria, Alere, ME). The RDT allowed the identification of cases of P. 
falciparum and those individuals who could be infected with a different or multiple 
species of the parasite. The T1 band (Figure 5.1) detects the presence of histidine-rich 
protein 2 (HRP2) – a protein specific for P. falciparum. The T2 band detects 
Plasmodium spp. aldolase, found in the four species of malaria capable of infecting 
humans. These different techniques provided an interesting opportunity for 
comparison between methodologies of Plasmodium spp.  detection.     
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Figure 5.1: Outcome following a BinaxNOW Malaria test. The top panel represents a 
positive P. falciparum infection, below that a Plasmodium infection that is not P. 




5.1.6 Geographic location of infections and the effect of forest area on fatality rate 
The samples from this study are taken from Guinea (in the majority), Liberia and Sierra 
Leone. These West African countries are covered, in part, by forest. This can increase 
the rates of transmission due to contact with zoonotic reservoirs and also access to 
potentially infected bush meat. Additionally, those further from ETCs and access to 
clinical attention may experience higher fatality rates. On the other hand, living in 
urban environments poses its own dangers, as people are housed in a more confined 
environment and therefore human-to-human transmission becomes more likely.  
 
5.1.7 Objectives and hypotheses 
The hypothesis was that the presence of co-infections could impact the host immune 
response, which could be observed at the level of gene expression. Moreover, these 
co-infections could be the driving force behind some of the IFN expression we observe 
in genuine infections but not experimental ones.  Furthermore, bacterial species found 
in blood samples represent translocation of species from the gut and therefore 
significant damage to the gut wall. Thus, the abundance of these could be higher in 
those who go on to succumb to infection, in comparison to those who survive.  
 
The objective was to identify the co-infections present in blood samples from patients 
during the 2013-2016 EBOV outbreak in West Africa. This could help to inform the 
treatment of patients in future outbreaks. Additionally, this permitted the evaluation 
of the use of Illumina RNA-sequencing as a method of identifying those 
microorganisms that are potential co-infections. The detection of P. falciparum 
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presented an opportunity to do this as we have information from both from the 
sequenced blood and the RDT performed upon patient admission.  
 
Data from this chapter has been published as part of the following publication: 
Carroll MW, et al. 2017. Deep sequencing of RNA from blood and oral swab samples 
reveals the presence of nucleic acid from a number of pathogens in patients with acute 
Ebola virus disease and is consistent with bacterial translocation across the gut. 
mSphere 2:e00325-17. https://doi.org/10.1128/ mSphereDirect.00325-17.  
The initial identification of transcripts from microorganisms was performed by 







5.2.1 Identification of microorganisms in the bodily fluids of patients with EVD 
In order to assess the microorganisms present in the blood of acute EVD patients, RNA 
was extracted from the diagnostic blood sample and sequenced as previously 
described. The presence of EBOV was confirmed via qRT-PCR. In this study, a total of 
202 individuals were included, as summarised in Table 5.1. The groups described as 
“Hospitalised fatalities” and “Hospitalised survivors” represent blood samples taken 
from patients upon arrival to the ETC suffering from acute illness. These individuals 
then went on to overcome the infection or succumb to it. “Community deaths” are 
oral swabs taken from individuals who died within the region surrounding the ETC in 
Guéckédou, forested Guinea, who tested positive for EBOV. Individuals who went on 
to survive infection were followed through their convalescence to confirm that they 
were virus-free. These “Convalescent controls” consist of blood samples taken from 
patients who once tested positive for EBOV but subsequently cleared the virus and 
were confirmed to be negative via qRT-PCR. These convalescent patients have been 
deemed to not be significantly different from a healthy Canadian cohort in terms of 
their transcriptomic profile (Liu et al., 2017). Therefore, these convalescent patients 
are able to act as controls in this study. These individuals would never had had any 
contact with EBOV. This “never” group was recruited as part of a different study 




Table 5.3: Summary of patients involved in this study. These have been split according 
to sample type and patient outcome. Here, patient age and EBOV Ct are described by 










N 118 44 16 24 
% Male 40.1 29.5 93.8 29.1 
Age 
(years) 
Range 2 mo – 80 10 mo – 68 18 – 40 1 - 70 
Mean 28.4 33.1 30.0 33.4 
EBOV Ct 
Range 12.1 – 26.6 15.8 – 31.6 NA 12.4 – 31.9 




After sequencing, reads mapping to EBOV and the human genome were removed and 
Trinity employed for de novo assembly in order to identify transcripts mapping to 
potential infectious agents.  
 
In order to evaluate this proposed technique, patient Ct value (a proxy for viral load 
obtained via qRT-PCR) was compared to the reads mapping to EBOV after RNA-
sequencing (Figure 5.2). A linear relationship is observed between the reciprocal Ct 
value and the logged read values (linear regression performed, R2 = 0.53, P<0.0001). 
This relationship led to the hypothesis that a greater number of reads mapping to a 
microorganism corresponds to a greater abundance of that microorganism in the 
blood.    
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Figure 5.2: Linear relationship between viral load and sequence depth mapping to 
EBOV. Viral load was determined using the reciprocal of the Ct value following qRT-PCR 
and sequence depth (log10 number of reads) mapping to the EBOV genome. Linear 
regression performed in R (red line), R2 = 0.53, P<0.0001.  
 
  


























A number of pathogens were identified as being present in these patients (a selection 
shown in Table 5.2, all transcripts available to download from https://doi.org/10.1128/ 
mSphereDirect.00325-17). Reads mapping to EBOV were found in every sample, thus 
providing support for the effectiveness of Illumina sequencing as a platform for the 
identification of microorganisms present in the extracted RNA of whole blood. The 










length E value 
EBOV L protein 96.8 2,212 0.00E+00 
GB-C Polyprotein 99.1 328 1.50E−190 
HHV-4 BALF2 100 100 1.9E−51 
 
LF2 protein 100 166 4.9E−91 
 
BALF5 98.8 172 4.4E−88 
 
BALF4 100 257 6.6E−142 
 
DNA polymerase catalytic subunit 99.2 131 2.3E−71 
 
BHRF1 100 121 7.40E-66 
 
BARF0 99.2 120 6.5E−62 
 
Early antigen D 100 118 2E−60 
 
gp110 precursor 100 95 1.3E−49 
 
A73 protein 100 94 6.1E−50 
 
LF1 98.9 92 1.1E−48 
 
Putative BHLF1 protein 98.7 75 4.8E−42 
 
BFRF1 100 71 4.1E−32 
 
BMRF2 100 68 7.6E−31 
 
dUTPase 98.5 68 3E−32 
 
BFRF2 100 67 4.2E−32 
 
LF3 protein 100 45 2E-16 
 
K15 100 37 5.6E-13 
Human 
immunodeficiency virus 1 Envelope glycoprotein   94.2 69 6.30E-30 
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Escherichia coli Glycosyl transferase family 2 100 583 0.00E+00 
 
Leucyl-tRNA synthetase 100 383 9.40E−224 
Lactobacillus fermentum 
DNA-directed RNA polymerase 
subunit beta 100 722 0.00E+00 
 
6-Phosphogluconate dehydrogenase 100 457 3.70E−260 
Candida albicans  Acetyl coenzyme A carboxylase 100 504 2.50E−293 
Streptococcus 
pneumoniae  Transposase DDE domain protein 100 493 2.90E−292 
Streptococcus sanguinis Collagen-binding protein 100 439 2.80E−251 
Streptococcus 
parasanguinis Amino acid transporter 100 402 8.80E−228 
Myroides spp. GMP synthase 100 508 3.20E−292 
 
Diaminopimelate decarboxylase 100 388 9.30E−223 
Haemophilus influenzae 
Phosphoribosylformylglycinamidine 
synthase 100 500 1.80E−289 
Haemophilus 
parainfluenzae l,d-Transpeptidase 100 393 3.80E−224 
Acinetobacter baumannii  2-Isopropylmalate synthase 100 479 1.20E−276 
Ureaplasma urealyticum Cell division protein FtsH 100 478 8.20E−264 
Plasmodium falciparum Hypothetical protein C923_00328 100 511 4.50E−298 
 
Hypothetical protein PFFVO_04502 100 476 2.20E−270 
 
Hypothetical protein PFTANZ_03315 100 450 5.70E−260 
 
Elongation factor 1 alpha 100 433 4.60E−249 
 
Histidine-tRNA ligase 100 403 1.10E−235 
 





Following the identification of these microorganisms, the effect of age was 
investigated in several pathogens (Figure 5.3). Patients were split according to their 
immunological maturity (Carroll et al., 2017). As expected, the peak presence of P. 
falciparum can be found in patients between 1.5 – 4 years of age, as shown previously 
in West Africa (Gupta et al., 1994) and predicted in areas of very high transmission 
(Woolhouse, 1998). 100% of the individuals in this age group had reads mapping to P. 
falciparum. This remained high throughout all age groups. In previous studies, co-
infection with GBV-C has been observed to have a beneficial impact on EVD patients. 
In our study a very small number of individuals with reads mapping to GBV-C were 
identified (n = 6), with all of these individuals going on to succumb to infection. The 
identification of HHV4 (formerly EBV), through BALF2 detection - codes for a major 
DNA-binding protein - signifies an active infection. Transcripts mapping to HHV4 were 
found in approximately 30% of individuals involved in this study, which were 
confirmed to be active infections due to the nature of the transcript identified. 
Previous studies (Sadek et al., 1999; Li et al., 2016) have noted that patient fatality rate 
was linked to age. However, our study cannot support this. The fatality rate for the 
over 40s was 70%, while that of 18 – 40 and the under 18s were not significantly 
different at 66% and 67% respectively. This lack of correlation could be due to the 
small number of individuals in this dataset over the age of 60, thus making conclusions 





Figure 5.3: The presence of nucleic acids from certain pathogens varies with patient 
age. Patients were grouped according to their immunological maturity (≤1 year [n = 8], 
1.5 to 4 years [n = 13], 5 to 45 years [n = 120], and 46+ years [n = 39]), and the 





After looking at the burden of disease across age ranges, the effect of potential 
bacterial co-infection was investigated. Here, patients were split into three groups: 
hospitalised fatalities, hospitalised survivors and convalescent patients. Once split, the 
various traces mapping to bacterial species were investigated in Figure 5.4. These 
traces are likely to be due to translocation of bacteria from the gut to the blood, which 
is indicative of gut trauma during viral infections (Balagopal et al., 2008; Carroll et al., 
2017). Among the convalescent patients, there were very few instances of bacterial 
presence, suggesting that this phenomenon is associated with acute illness. In the 
group of patients who went on to suffer a fatal infection, there appears to be a higher 
proportion of individuals with reads mapping to multiple bacterial species.  This is 
particularly remarkable when it is noted that one of the hospitalised survivors who had 
a high abundance of bacterial species present in their blood had lots of reads mapping 
to bacterial species with the ability to cause urinary tract infections – including 
Pseudomonas aeruginosa, Prevotella amnii and Mycoplasma hominis (Figure 5.4). In 
Chapter 3, Section 3.2 it was highlighted that a small number of individuals had 
reported very long symptomatic periods – up to 256 days. The potential co-infections 
of these individuals were of particular interest, as this was hypothesised as an 
explanation for this self-reported figure. However, of those individuals stating they 
were symptomatic for greater than 50 days, none had reads mapping to a high 






Figure 5.4: Heat map showing the bacterial species identified in the blood of acute 
EBOV patients (along the y-axis). Along the x-axis is the patient group: convalescent 
patients in green, hospitalised survivors in yellow and hospitalised fatalities in orange 





Bacterial transcripts detected in the oral swabs of deceased EVD patients are shown in 
Figure 5.5. This detection was very common, with the majority of samples allowing the 
identification of multiple bacterial species, many of which occur naturally in the upper 
respiratory tract. Collaborators went on to culture five of these samples in high-
containment conditions, allowing the identification of several species by MALDI-TOF 
(Carroll et al., 2017). This cements the functionality of this pipeline in the detection of 




Figure 5.5: Heat map showing the transcripts identified from oral swabs of deceased 
individuals (n = 24). Patient samples along the x axis with bacterial species along the y 
axis. The depth of colour represents the read depth, with yellow indicating a greater 




5.2.2 Effect of co-infections at the level of gene expression 
The differences in host response of those infected with EVD and healthy controls has 
been previously discussed, as well as the difference between acutely infected 
individuals who go on to succumb to or clear EBOV infection (Liu et al., 2017). Such 
associated pathways include the innate immune response, blood coagulation and the 
acute phase response. As these have already been identified, they provide an 
interesting area of investigation with regards to the potential effect of the presence of 
bacterial transcripts in the blood. These data (Figure 5.6) suggest that the abundance 
of certain transcripts associated with the acute phase response could be altered 
according to the presence of bacterial species. The expression of ICAM-1 and TGF-1 
were significantly higher in those with no bacterial transcripts in their blood, in 





Figure 5.6: Relative abundance of transcripts mapping to host genes associated with 
the host acute phase response, coagulation, the interferon response and 
inflammation in patients with EVD in whom we could detect the transcripts from at 
least two bacterial species in their blood (n = 22; grey) or not (n = 9; black) (by RNA 
sequencing). Relative gene expression levels are displayed as the fragments per 
kilobase of transcript per million mapped reads (FPKM). Graphs show mean FPKM plus 
standard deviation. Statistical analysis was performed using a two-way ANOVA with 





As previously mentioned, the utilisation of an RDT in the field provided an interesting 
comparison between diagnostic techniques. This comparison is illustrated in Figure 
5.7. Here, patients have been split according to their abundance of transcripts 
mapping to P. falciparum. The patient fatality rate across these groups is shown in red, 
and appears to increase across these groups, with those with very high abundance of 
P. falciparum transcripts (36,000+ mapped reads) all going on to succumb to infection. 
Those with this high abundance likely represent patients with a severe malaria 
infection, probably exhibiting the many symptoms that go along with such a diagnosis. 
Unsurprisingly, as reads mapping to P. falciparum increase, the more likely that those 
individuals would test positive for the antigen via the RDT. There were 73 individuals 
who had reads mapping to P. falciparum and tested RDT-negative (referred to as the 
RDT false negative rate). 84% of individuals had reads mapping to P. falciparum, while 
only 33% tested positive via the RDT. This could potentially illustrate an under-
representation of the burden of malaria in our Guinean population by the RDT. 
Alternatively, the RDT could be identifying severe malaria infections with greater 
accuracy, and the RNA-sequencing could be picking up asymptomatic or past 




Figure 5.7: Effect of an increased number of reads mapping to P. falciparum. The 
green line (associated with the left-hand y axis) shows the proportion of patients who 
tested negative for malaria according to the RDT but for whom reads mapping to P. 
falciparum were detected during RNA-seq analysis. The red line (left-hand y axis) shows 
the patient fatality rate. The black bars (right-hand y axis) represent the number of 
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In order to assess the effect of the presence of P. falciparum in the blood, two groups 
of samples were formed: (1) those testing positive for P. falciparum by RDT and having 
high number of reads mapping to the parasite, representing individuals whose immune 
systems have been stimulated by the co-infection and (2) those testing RDT-negative 
and having no reads mapping to P. falciparum. The latter group representing 
individuals who are definitely not co-infected with malaria. These groups did not differ 
significantly in EBOV Ct or age.  This investigation included genes that have previously 
been implicated in being critical to the host response to severe malaria (Grangeiro de 
Carvalho et al., 2011; Krupka et al., 2012; Rommelaere et al., 2015). These data 
suggested that there is no significant difference in the host transcript abundance 
between these two groups (Figure 5.8). The investigation then pivoted to consider the 
genes involved in blood coagulation, which have been previously highlighted as being 
expressed in higher levels in fatal infections (Liu et al., 2017). Here, those without 
reads mapping to P. falciparum appeared to produce those transcripts in higher 




Figure 5.8: Relative abundance of transcripts mapping to host genes associated with 
acute malaria and the innate immune system in patients with EVD. Comparison of 
two groups: those confirmed to be positive (grey; n = 10) or negative (black; n = 13) for 
P. falciparum (by RNA sequencing and RDT). Relative gene expression levels are 
displayed as the fragments per kilobase of transcript per million mapped reads (FPKM). 




Figure 5.9: Relative abundance of transcripts mapping to host genes associated with 
coagulation in patients with EVD and testing positive (grey) or negative (black) for P. 




In order to investigate the effect of HHV4 as a co-infection, two matched groups (as 
much is possible, in terms of gender, age, viral load and patient outcome) were 




Figure 5.10: Comparing the profiles of the patients with reads mapping to HHV4 who 
survived or died from EVD. There were no significant differences in terms of read depth 
of HHV4 hospitalised survivors and fatalities, Mann-Whitney U test performed, p > 0.2. 
Also, individuals with reads mapping to HHV4 did not differ in terms of fatality rate. 























































The host transcripts were compared to that of a control group and a digital cell 
quantification (DCQ) performed (Figure 5.11). Upon comparison of the distinctive 
immune cell profiles of these groups, some differences are notable. A two-way ANOVA 
was performed with Sidak’s multiple comparisons test, reported p-values are adjusted. 
Megakaryocytes (p = 0.015) and hematopoietic stem cells (CD38-CD34+, p = 0.044) 
were predicted to be significantly more abundant in EVD patients with HHV4 
transcripts, while Naïve CD8+ T lymphocytes significantly less abundant (p = 0.021). 
Naïve B lymphocytes and neutrophils also appeared to be of lower abundance in 




Figure 5.11: Comparison of predicted immune cell profile between HHV4 positive and 
negative EVD patients. DCQ performed to compare the relative cell quantity between 
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EVD-positive individuals who had reads mapping to HHV4 in their sample (HHV4+, blue; 
n = 14) and those who did not (HHV4-, green; n = 23). A two-way ANOVA was 
performed with Sidak’s multiple comparisons test to compare groups using Prism 7 




5.2.3 Geographic location 
As a further area for investigation, the geographic location of patients was examined 
(Table 5.3), with a particular focus on the forested regions of Guinea, Liberia and Sierra 
Leone.  25.9% of Guinea is considered to be forest area, which has decreased steadily 
over the past two decades from 28.8% in 1995 (The World Bank, 2016). The forested 
nature of Guinea has been implicated as one of the factors allowing these types 
outbreaks to occur due to the close contact with potential reservoir species (Weyer et 
al., 2015). This showed that patients from the group of hospitalised fatalities had the 
broadest geographic spread, perhaps unsurprisingly due to this group being the 
largest. Geographic location had no effect on the abundance of transcripts mapping to 
potential pathogens. However, there do appear to be some areas in which the 
proportion of fatalities is higher than others, thus indicating a higher burden of 




Table 5.5: Table showing geographic location of individuals involved in this study. 









of H_S (%) 
GIN Macenta 27 25 7 26.9 
GIN Gueckedou 34 31.5 8 30.8 
GIN Nzerekore 5 4.63 2 7.69 
GIN Lola 2 1.85 0 0 
GIN Beyla 3 2.78 0 0 
GIN Kerouane 7 6.48 1 3.85 
GIN Faranah 1 0.93 2 7.69 
GIN Kankan 1 0.93 0 0 
GIN Siguiri 1 0.93 0 0 
GIN Kouroussa 0 0 1 3.85 
GIN Kissidougou 14 13.0 2 7.69 
LBR Foya 7 6.48 1 3.85 
LBR Voinjama 3 2.78 0 0 







In this chapter the presence of transcripts from microorganisms (including viral, 
bacterial and protozoan) in the blood of patients with EVD is investigated. This was 
performed using samples taken for diagnostic purposes and therefore represents an 
analysis that is unbiased in its sequencing approach.  
 
The average length between the patient’s first symptoms and their admission to the 
ETC was roughly six days (Chapter 3, Figure 3.2), suggesting that these samples 
represent patients who were still in the relatively early stages of infection. However, 
these data are based on self-reported information and therefore may not be entirely 
accurate - there were cases of individuals claiming to be suffering from symptoms for 
many months and even years. These extreme responses were not included in the 
analysis as these symptoms are likely to be due to other co-morbidities. The maximum 
incubation period for Ebola has been described as 25 days, which accounts for 99% of 
individuals, so this was used as a cut-off for inclusion (Eichner et al., 2011). 21 days is 
often quoted as the incubation period for Ebola but may only account for 95% of 
cases. By six days, an EBOV-infected patient is likely to be in the mid-stage of infection, 
commonly experiencing gastrointestinal complications (Hunt et al., 2015). This is 
categorised by diarrhoea and vomiting as well as the non-specific symptoms 
associated with the early stages of infection, i.e. pyrexia and lethargy (Hunt et al., 
2015). With these symptoms, bacterial translocation from the gut to the blood is not 
unlikely. Therefore, the use of blood samples in this study can provide insight into 
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potential co-infections. Patients were followed throughout their infection and 
(potential) convalescence and sequential blood samples taken. This was done to 
confirm that a patient was EBOV negative in their blood and therefore permitted to 
leave the ETC. Two consecutive blood samples testing negative for EBOV via qRT-PCR 
were required for patient discharge. These convalescent samples have been used as a 
control group in this study, providing a background profile of the transcript levels in 
the blood. As mentioned previously, the blood samples from acutely ill and 
convalescent patients were not taken in a standardised environment. During the acute 
stage of infection, patients can be delirious and difficult to treat, thus sample 
procurement becomes a more challenging task. This inequality may have impacted the 
microorganisms present in these samples. However, the transcriptomic profile for all 
acutely infected patients was not alike, so the impact of this may be negligible.  
 
Co-infections have long been known to have the ability to influence primary infections, 
with the potential to significantly impact patient outcome. These relationships can be 
deleterious but there are cases where co-infections are deemed to be beneficial. These 
effects can also vary according to the geographic location, population and diagnostic 
method of the study. For example, higher P. falciparum parasitaemia has been found 
to be positively correlated with survival in EVD patients (Rosenke et al., 2016), via the 
use of qRT-PCR to determine levels of the parasite. Whereas other studies have found 
that, especially in children between the ages of 5 and 14, a high parasitic load will 
regularly lead to a poor prognosis (Kerber et al., 2016), upon utilisation of the RDT. 
This is reflected in the study described herein, where the effect of P. falciparum on the 
outcome of the patient depends on the method by which it was detected. When the 
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RDT was used as a determining factor, a positive result appeared to be indicative of a 
fatal outcome (p = 0.053; Chapter 3, Figure 3.3). However, this effect was not 
sustained once the RNA-sequencing data was employed to show the presence of P. 
falciparum. The explanation for this is two-fold. Firstly, a much higher proportion of 
individuals had reads mapping to P. falciparum following RNA sequencing (84%, 156 
out of 186) compared to those testing positive via RDT (33%, 40 out of 121). This 
minimises the power behind the statistical analysis of the RNA sequencing results. The 
second, and perhaps the more important, explanation is that these methods differ 
dramatically. As the sequence depth mapping to P. falciparum increased, the 
differences between the RDT and RNA sequence data were lessened. The RDT is 
employed to detect patients with high levels of parasitaemia (>1000 parasites/l 
blood), and so those with incidental parasitaemia/past infections may not be 
identified, unlike with sequencing.  Following this, it is unsurprising that the detection 
of P. falciparum by RNA sequencing does not have a pronounced effect on patient 
outcome. Individuals with high parasitaemia are likely to have been experiencing acute 
malaria and suffering the accompanying symptoms. This acute phase includes a 
powerful proinflammatory response, which is known to be an effective dampener of 
viral activity. However, these responses do not always act in a synergistic fashion. 
Individuals with low parasitaemia are likely to have an asymptomatic infection (if 
there’s a current infection at all) and experience little inflammation. Therefore, any 
interaction with a positive EBOV infection is unlikely. In order to investigate this, two 
groups were isolated from the sample population: (1) those testing positive for P. 
falciparum by RDT and having high number of reads mapping to the parasite and (2) 
those testing RDT-negative and having no reads mapping to P. falciparum. Comparing 
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these groups, there was no significant difference between the gene expression levels 
of genes associated with the innate immune response (Figure 5.7). This suggests that 
EVD is capable of completely overwhelming the immune response, so the addition of 
P. falciparum in the blood has very little effect at the level of gene transcription. There 
did appear to be, however, some difference in the abundance of transcripts associated 
with blood coagulation (Figure 5.8). This potential difference was due to a few 
individuals in whom the levels of gene expression were much higher. This could be due 
to an interruption of the host antiviral response due to the levels of high parasitaemia. 
Therefore, genes that are normally readily expressed in patients with an acute viral 
infection are dampened due to the presence of P. falciparum in the blood. The 
limitations of this study in terms of minimal samples should be noted. This is due to 
the finite number of samples in which no reads mapping to P. falciparum were found. 
These methods could present the opportunity to determine a cut-off point for the 
number of Illumina reads required to confirm the presence of a microorganism. In 
these data, the lowest number of reads mapping to P. falciparum which tested positive 
for the pathogen via the RDT was 198. This could provide a rough figure as to the 
minimum read depth at which a co-infection is considered to be present. However, 
this is not considering where those reads lie along the P. falciparum genome, which 
could be a critical factor.  
 
Transcripts from a number of bacterial species were identified in blood samples of 
acutely ill patients with EVD (Figure 5.4), suggesting translocation of bacteria from the 
gut to the bloodstream. However, these were not identified in all hospitalised patients. 
This unbiased approach to the identification of microorganisms means that no 
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causative conclusions can be drawn from the data presented herein, but a microbial 
profile can be built. Many individuals had transcripts in their blood mapping to 
bacterial species capable of causing sepsis, including Haemophilus influenzae and 
Streptococcus pneumoniae. Furthermore, although the identities of these transcripts 
are well supported, the close phylogenetic relationship between bacterial species 
(considered to be both pathogenic and non) needs to be considered. An example of 
this was the identification of P. reichenowi. This Plasmodium species is known to infect 
chimpanzees, not humans. It is difficult to determine whether these transcripts were 
genuinely present in the blood samples or simply a case of mistaken identity due to 
the analysis pipeline. It is possible that the two species are so phylogenetically similar 
that they could not be differentiated. Despite these factors, the identification of 
numerous bacterial species associated with sepsis is concerning. This discovery 
supports the use of antibiotic therapy for patients with EVD. CDC guidelines suggest 
that antibiotics should be employed in order to distinguish nonspecific symptoms of 
EVD from bacterial sepsis (Uyeki et al., 2016). The importance of this is clear, as 
sufferers of EVD are clearly at high risk of translocation of bacteria from the gut to the 
blood, following gastrointestinal involvement of EVD. This creates a potentially life-
threatening situation. Pseudomonas spp. transcripts were detected in the blood of a 
number of patients. This Gram-negative bacterial genus contains many infectious 
species often found in hospital environments. In immune-compromised individuals, 
infection with P. aeruginosa can lead to sepsis and septic shock (Kielhofner et al., 
1992; Roy-Burman et al., 2001; Kalle et al., 2012; Aggarwal, 2016).  
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The transcripts of potential pathogens found in oral swabs of deceased individuals are 
unsurprisingly more abundant and diverse than those taken from blood samples 
(Figure 5.5). The taking of swabs post-mortem from individuals who died in the 
community became an essential tool in the epidemiological understanding of the 
outbreak, also informing burial practises. The limitations of studying these samples are 
plentiful, including the fact that it is impossible to tell when these bacteria would have 
started growing. This could have occurred during the late stages of EVD or, in fact, 
following the death of the individual. The presence of a number of these species were 
also found following mass spectrometry of the swabs, performed by colleagues (Carroll 
et al., 2017). This helps to further validate the findings of the RNA sequencing analysis. 
Among the microorganisms identified by mass spectrometry were bacteria and fungi. 
These can be found routinely as part of the flora that constitutes the respiratory tract. 
In acutely ill patients, these have the potential to be opportunistic pathogens and be 
the cause of serious complications. These microorganisms are likely to represent a 
small portion of the microbial profile of the respiratory tract, as they would have to be 
capable of surviving harsh conditions. This includes multiple freeze-thaw cycles due to 
sample processing, which is known to affect the integrity of biological samples 
(Shabihkhani et al., 2014). This illustrates one of the benefits of the use of RNA 
sequencing in this manner, as only extracted RNA from neutralised samples is 
required. From this, much information has been returned, with no need for laboratory 
work in high containment conditions.  
 
In addition, there were transcripts from a number of viral species in patient samples. 
These were seen to vary across different age groups (Figure 5.3), but there was no 
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correlation between the presence of these viruses and the outcome of the patient. In 
previous studies, GBV-C has been seen to provide individuals with a higher chance of 
survival compared to their uninfected counterparts. This was not observed in this 
study, as all individuals with transcripts mapping to GBV-C went on to succumb to EVD. 
However, this group comprised of only six individuals, so no concrete conclusions can 
be drawn. Transcripts mapping to HHV4 were found in almost a third of patient 
samples, with mapping to BALF2. The downstream protein plays a crucial role in the 
initiation of viral entry and replication. This suggests that individuals with these 
transcripts were infected with HHV4. This interaction between EVD and HHV4 has 
been noted previously, with the reactivation of HHV4 becoming more likely as the CD4 
T-cell response of the host becomes impaired (Agrati et al., 2016). This effect could not 
be corroborated using our data (Figure 5.9). HHV4 as a coinfection with other viruses 
has been shown to have a deleterious effect on patient morbidity, including 
cytomegalovirus (CMV) (Wang et al., 2010) and HIV (Chakraborty et al., 2010). In our 
samples, however, the fatality rate was not seen to differ with the identification of 
HHV4 transcripts (Figure 5.10). 
 
Human immunodeficiency virus (HIV) is a significant co-infection due to its ability to 
dampen the host immune response and therefore leave individuals vulnerable to other 
infections. In this study, only one transcript mapping to HIV-1 was detected (Table 5.2). 
This corresponds to the envelope glycoprotein of the RNA virus. The prevalence of HIV 
in Guinea is around 1% (based on 120 000 people living with HIV) (UNAIDS, 2016). At 
this rate, it is possible that we simply did not have more than one HIV-positive 
individual in our sample population. Alternatively, it is possible that our sequencing 
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pipeline is not appropriate for the identification of HIV, which is notoriously difficult in 
the absence of preamplification (Gall et al., 2012).  
 
These data provide an interesting insight into the different microorganisms and 
potential pathogens present in the blood of individuals suffering from EVD. The 
identification of bacteria associated with sepsis gives support for the treatment of 
patients with antibiotics upon their admission to the ETC in future outbreak situations. 
The detection of P. falciparum in individuals who tested negative via the RDT could 
impact how we perceive the effect of this parasite.     
 
 193 
Chapter 6: Thesis discussion 
6.1 Discussions and future perspectives 
The aims of this thesis were to further the understanding of EBOV pathogenesis and 
potential determinants of patient outcome. This was achieved by the use of 
transcriptomic analysis of samples for EVD patients. Broadly, these investigations 
focused on the effects of the virus itself, the host response and co-infections. In 
order to elucidate these factors, diagnostic samples taken from the 2013-2016 EVD 
outbreak in West Africa were sequenced using both Illumina and Nanopore 
techniques as well as infected model organisms and cell lines.  
 
This approach allowed for the comparison of acutely ill individuals at the time of 
sampling. Some of these individuals went on to die from infection, whilst others 
survived, thus creating two distinct groups: hospitalised fatalities and hospitalised 
survivors. Convalescent patients, testing negative for EBOV in their blood by qRT-
PCR, were an invaluable control group. Upon RNAseq by Illumina, comparing the 
transcriptomes of these groups was facilitated. This highlighted a number of 
pathways that appeared to be upregulated in hospitalised patients compared to 
their convalescent counterparts. Many of these were associated with the acute 
immune response, which was to be expected due to the nature of the contrast – i.e. 
the comparison between any acutely ill individuals to comparatively “healthy” ones. 
Furthermore, these same pathways were enriched in the hospitalised fatalities 
compared to survivors (Figure 4.1), supporting previous findings that associated 
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uncontrolled inflammation and cell migration with immunopathology (Nfon et al., 
2013). This was supported when compared to experimentally infected guinea pigs, 
where a general trend of increasing abundance of transcripts mapping to cytokines 
was observed as pathogenicity and fatality rate increased (Figure 4.12). This is 
critically important as it further supports the use of guinea pigs as an appropriate 
model organism when it comes to studying the host response to EVD. Guinea pigs 
are often employed for use in the first stage of testing treatments and/or vaccines 
prior to the involvement of NHPs. The response of NHPs to EBOV challenge has been 
shown to mirror the human response effectively, but the use of these models is 
accompanied by both ethical and financial considerations. The identification of 
pathways associated with a poor patient prognosis has potential clinical implications 
in the form of informing patient care. For example, the provision of anti-
inflammatories could have a beneficial outcome if given at an appropriate time 
during the disease course. Of course, the context of most EVD outbreaks must be 
noted. These often occur in developing countries with limited resources and 
infrastructure and therefore implementing this knowledge in real scenarios may not 
be possible. Therefore, these guidelines may only be of assistance in the treatment 
of expatriated patients.  
 
These enriched pathways were predicted from the identification of differentially 
expressed genes between the groups. This dataset allowed a linear discriminant 
analysis to be performed and correlates of patient outcome to be determined. With 
these data, patient outcome could be predicted with very high accuracy, especially in 
the presence of EBOV Ct (Figure 4.9). These concepts could be applied to other viral 
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infections and potentially more broadly to bacterial infections, with particular use in 
settings when pathogen burden is not a good indicator of outcome. Additionally, this 
LDA was constructed exclusively using samples from the West African outbreak. The 
ongoing outbreak in the DRC provides a potential cohort on which to test this tool. 
Host response to infection varies with geographical area, and so the applicability of 
this analysis on separate populations is still to be confirmed. The optimal way to test 
this would be to receive blinded RNA samples from the blood of infected individuals 
in the DRC that are confirmed to be EBOV-positive by qRT-PCR. Optimised targeted 
qRT-PCR experiments could then be performed for VCAM, TUBG1 and ISG15 and a 
prediction made for the outcome of the patient. If successful, a multiplex PCR could 
be designed and constructed to act as a predictive tool for patients with EVD. This 
would not delay the diagnostic period as it would consist of a single qRT-PCR run. 
However, the financial viability of this would have to be thoroughly investigated.   
 
The opportunity to collect and analyse these samples provided an exciting prospect 
to utilise different platforms for their analysis. One such avenue was using Nanopore 
sequencing via the MinION. This technique was implemented during the 2013-2016 
outbreak, and functioned well in the phylogenetic analysis of samples, aiding in 
contact tracking and the understanding of the spread of EVD (Carroll et al., 2015; 
Quick et al., 2016). For example, molecular phylogenetics allowed the beginning of 
the outbreak to be predicted with great accuracy, supporting the findings of a 
previous epidemiological study (Baize et al., 2014). In this study, the aim of using this 
technique was to generate long reads and therefore draw further conclusions about 
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EBOV that could not be achieved using the data generated by an Illumina platform. 
This included investigating the mutations along the EBOV genome associated with 
patient prognosis as well understanding the true formation of DIs. However, the sub-
optimal quality of the RNA extracts that were sequenced posed a significant 
challenge for the MinION. Due to this, the average read length generated was not 
much longer than those following Illumina sequencing, and coverage of the virus was 
poor. However, the longest reads were substantially longer than the 150 base pairs 
generated by Illumina platforms, thus giving hope to further investigations with this 
tool. Further troubleshooting and refining of this protocol could potentially produce 
much more successful and substantial results. The PCR kit used for the Nanopore 
sequencing in this study would have introduced certain biases, including a skewed 
preference towards shorter transcripts. In order to maximise this technology a more 
targeted approach would be beneficial. This could either involve EBOV-specific 
primers or a metagenomic approach (Kafetzopoulou et al., 2018). Additionally, 
advances in the accuracy and ability of this platform are constantly being made, 
providing the opportunity to sequence RNA directly (Garalde et al., 2018). Initially, 
the error rate of this platform was prohibitively high. However, this has been 
substantially improved since the tool’s inception and continues to develop as a 
viable transcriptomic device (Jain et al., 2016; M. Jain et al., 2018).  
 
Although the use of the Nanopore platform did not provide as much information as 
initially hoped, Illumina sequencing allowed investigation into the role of the virus 
itself in EVD. The difference in EBOV genome variation between patient groups was 
significant, with surviving individuals having higher viral diversity (Figure 3.6). This is 
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potentially due to the host response itself, with the viral population needing to 
overcome population bottlenecks imposed by the immune response (Domingo et al., 
2012). Certain mutations, which were identified as being common in the 2013-2016 
outbreak, were found to be more common in hospitalised fatalities when compared 
to survivors (Figure 3.8). This could indicate that these mutations convey a fitness 
advantage to the virus itself, i.e. a virus capable of replicating or spreading more 
quickly. This is demonstrated by Dowall et al. (2014) in that variations in EBOV 
nucleotide sequences were associated with increased pathogenicity as the virus 
adapted to the infected guinea pigs.   
 
One particular avenue of EBOV biology that became elucidated following the 2013-
2016 outbreak was that virus persistence and sequalae. A hypothesised explanation 
for this is the generation of truncated viruses or DIs, which are potentially capable of 
interrupting viral replication. The identification of these genomes has most often 
been observed in in vitro infections, as was readily shown in infected THP-1 cells via 
the identification of fusion events (Figure 3.12). However, when these fusion events 
were searched for in clinical samples, very few were identified (Table 3.3). Of those 
identified, even fewer would be likely to be able to confer much of an evolutionary 
advantage due to their small size. These were expected to be found in the semen of 
convalescent patients, as these are the body compartments in which the virus is 
persisting. Therefore, DIs are potentially not the mechanism responsible for allowing 
EBOV to remain in the body. However, these semen samples had a lower read depth 
across the EBOV genome when compared to the infected THP-1 cells. This could 
directly impact the ability of fusion events to be detected and potential DIs to be 
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identified. Additionally, further investigation into different types of DIs could be 
beneficial, as this study only explored those formed via deletion events.  
 
In the past, EVD was referred to as Ebola Haemorrhagic Fever. This change in 
nomenclature has come about due to the fact that few victims of recent outbreaks 
have experienced haemorrhagic symptoms (Fletcher et al., 2014). One notable 
aspect of the 2013-2016 outbreak was the progression of patients from non-specific 
symptoms with fever to the gastrointestinal stage of disease (Fletcher et al., 2014). 
This stage involves the dysfunction of the liver and kidneys. In this study, the extent 
of the gastrointestinal involvement is supported by the detection of transcripts from 
microorganisms in patient samples that would not normally be found in the blood. 
This suggested gut translocation of bacterial species was common in acute sufferers 
of the disease, while mostly absent in convalescent patients (Figure 5.4). 
Understanding the pathogenicity of EVD is essential not only in recognising 
outbreaks in their early stages, but also the handling of clinical cases. These data 
have important implications for the treatment of EVD patients, particularly 
considering antibiotic stewardship. Using this bioinformatics approach allowed EBOV 
to be detected in each sample. This, along with the confirmation of certain bacterial 
species by mass spectrometry (Carroll et al., 2017), gives support for the use of 




An enormous amount of information has been generated through the sequencing of 
EBOV-positive RNA extracts. As such, only a small proportion of this study into EBOV 
has been performed under CL4 conditions. These data could have significant clinical 
implications on the guidelines of the treatment of EVD patients, for example in the 
provision of anti-inflammatories and/or antibiotics. One factor these analyses 
highlight is the benefit of personalised medicine, and the understanding that patient 
factors such as age can have substantial impact on their immune response and likely 
co-infections. However, outbreaks of EVD occur in populations that share borders 
with the suspected animal reservoirs of the virus – namely those in forested regions. 
These are usually developing countries with limited infrastructure and a dearth of 
education concerning infectious disease among the local population. Therefore, the 
opportunity to treat individuals differently in outbreak situations becomes almost 
impossible. A perhaps more practical solution would be to house those patients with 
similar requirements in close proximity. This would be beneficial for infected 
individuals and healthcare workers alike, especially in outbreak situations. 
 
This thesis highlights the fact that animal studies, cell culture and the analysis of 
clinical samples should be considered in tandem in order to effectively study all 
aspects of EBOV biology.  
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Chapter 7: Appendix 
 
7.1 Differentially expressed genes following EdgeR analysis 
 
Table 7.1: Top 20 differentially expressed genes of hospitalised fatalities compared to convalescent controls.  
Ensembl gene ID logFC logCPM P value FDR Gene name Description 




08 FGA fibrinogen alpha chain [Source:HGNC Symbol;Acc:HGNC:3661] 




09 ALB albumin [Source:HGNC Symbol;Acc:HGNC:399] 




09 FGB fibrinogen beta chain [Source:HGNC Symbol;Acc:HGNC:3662] 




08 FGG fibrinogen gamma chain [Source:HGNC Symbol;Acc:HGNC:3694] 





alcohol dehydrogenase 1B (class I), beta polypeptide [Source:HGNC 
Symbol;Acc:HGNC:250] 




10 APOB apolipoprotein B [Source:HGNC Symbol;Acc:HGNC:603] 





cAMP responsive element binding protein 3 like 3 [Source:HGNC 
Symbol;Acc:HGNC:18855] 




08 C7 complement C7 [Source:HGNC Symbol;Acc:HGNC:1346] 




11 FABP4 fatty acid binding protein 4 [Source:HGNC Symbol;Acc:HGNC:3559] 




10 CXCL12 C-X-C motif chemokine ligand 12 [Source:HGNC Symbol;Acc:HGNC:10672] 





nuclear receptor subfamily 2 group F member 2 [Source:HGNC 
Symbol;Acc:HGNC:7976] 




13 TIMP3 TIMP metallopeptidase inhibitor 3 [Source:HGNC Symbol;Acc:HGNC:11822] 
ENSG00000162692 7.55358865 3.3936028 1.21E- 2.68E- VCAM1 vascular cell adhesion molecule 1 [Source:HGNC Symbol;Acc:HGNC:12663] 
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11 KDR kinase insert domain receptor [Source:HGNC Symbol;Acc:HGNC:6307] 





adhesion G protein-coupled receptor L4 [Source:HGNC 
Symbol;Acc:HGNC:20822] 




05 SLC38A4 solute carrier family 38 member 4 [Source:HGNC Symbol;Acc:HGNC:14679] 




05 ISG15 ISG15 ubiquitin-like modifier [Source:HGNC Symbol;Acc:HGNC:4053] 




09 FCN3 ficolin 3 [Source:HGNC Symbol;Acc:HGNC:3625] 




13 ZDHHC19 zinc finger DHHC-type containing 19 [Source:HGNC Symbol;Acc:HGNC:20713] 

















Table 7.2: Top 20 DE genes in hospitalised survivors compared to fatalities. 
Ensembl gene ID logFC logCPM P value FDR Gene name Description 
ENSG00000276197 
-
5.3367384 5.02321837 1.32E-13 4.56E-11 pRNA NoRC assoicated RNA, pRNA [Source:RFAM;Acc:RF01518] 
ENSG00000188257 
-
4.6144515 3.26684373 1.98E-10 2.72E-08 PLA2G2A phospholipase A2 group IIA [Source:HGNC Symbol;Acc:HGNC:9031] 
ENSG00000104760 
-
4.2386355 6.84742069 4.92E-06 0.00014445 FGL1 fibrinogen like 1 [Source:HGNC Symbol;Acc:HGNC:3695] 
ENSG00000171564 
-
4.1642728 7.16264872 1.24E-08 9.26E-07 FGB fibrinogen beta chain [Source:HGNC Symbol;Acc:HGNC:3662] 
ENSG00000000971 
-
4.0553824 7.34331921 1.21E-13 4.27E-11 CFH complement factor H [Source:HGNC Symbol;Acc:HGNC:4883] 
ENSG00000171560 
-
3.8737645 8.98353936 1.16E-05 0.00029276 FGA fibrinogen alpha chain [Source:HGNC Symbol;Acc:HGNC:3661] 
ENSG00000060566 
-
3.8391213 5.54806362 6.68E-10 8.22E-08 CREB3L3 




3.6651907 4.51766564 4.46E-08 2.74E-06 ADH1B 




3.6569443 4.24741588 2.14E-09 2.04E-07 C1S complement C1s [Source:HGNC Symbol;Acc:HGNC:1247] 
ENSG00000091181 
-
3.5125941 4.76118365 3.46E-11 6.13E-09 IL5RA interleukin 5 receptor subunit alpha [Source:HGNC Symbol;Acc:HGNC:6017] 
ENSG00000139209 
-
3.4273524 5.17321021 3.22E-07 1.44E-05 SLC38A4 solute carrier family 38 member 4 [Source:HGNC Symbol;Acc:HGNC:14679] 
ENSG00000163631 
-
3.3874133 7.8196547 3.91E-06 0.0001198 ALB albumin [Source:HGNC Symbol;Acc:HGNC:399] 
ENSG00000106853 
-
3.3399954 4.57266783 7.41E-10 8.75E-08 PTGR1 prostaglandin reductase 1 [Source:HGNC Symbol;Acc:HGNC:18429] 
ENSG00000166741 
-
3.3337968 2.53225277 1.81E-09 1.78E-07 NNMT nicotinamide N-methyltransferase [Source:HGNC Symbol;Acc:HGNC:7861] 





3.2737389 1.89119184 1.36E-09 1.41E-07 ADAMTS5 




3.2054854 2.84530408 2.63E-08 1.76E-06 TUBG1 tubulin gamma 1 [Source:HGNC Symbol;Acc:HGNC:12417] 
ENSG00000276700 
-
3.0669568 7.0927172 6.50E-08 3.76E-06 RNA5-8SN1 RNA, 5.8S ribosomal N1 [Source:HGNC Symbol;Acc:HGNC:53517] 
ENSG00000162692 
-
3.0575901 4.45658564 1.60E-15 7.25E-13 VCAM1 vascular cell adhesion molecule 1 [Source:HGNC Symbol;Acc:HGNC:12663] 
ENSG00000187608 
-





7.2 KEGG pathway analysis 
 
Table 7.3: KEGG analysis enriched pathways of hospitalised fatalities compared to convalescent controls.  
ID Description GeneRatio BgRatio pvalue p.adjust qvalue 
hsa05144 Malaria 18/660 49/7383 8.63E-08 2.60E-05 2.23E-05 
hsa04610 Complement and coagulation cascades 23/660 79/7383 2.05E-07 3.08E-05 2.64E-05 
hsa05322 Systemic lupus erythematosus 30/660 133/7383 1.42E-06 0.00014255 0.00012214 
hsa04668 TNF signaling pathway 26/660 108/7383 1.97E-06 0.00014791 0.00012673 
hsa04060 Cytokine-cytokine receptor interaction 45/660 270/7383 2.60E-05 0.00156802 0.00134347 
hsa04514 Cell adhesion molecules (CAMs) 28/660 145/7383 6.78E-05 0.00340164 0.0029145 
hsa04640 Hematopoietic cell lineage 20/660 97/7383 0.00029594 0.01013005 0.00867936 
hsa05215 Prostate cancer 20/660 97/7383 0.00029594 0.01013005 0.00867936 
hsa05150 Staphylococcus aureus infection 14/660 56/7383 0.00030289 0.01013005 0.00867936 
hsa05202 Transcriptional misregulation in cancer 31/660 186/7383 0.0004668 0.01289018 0.01104422 
hsa03320 PPAR signaling pathway 16/660 72/7383 0.00048939 0.01289018 0.01104422 
hsa05418 Fluid shear stress and atherosclerosis 25/660 139/7383 0.00051389 0.01289018 0.01104422 
hsa05133 Pertussis 16/660 76/7383 0.00091879 0.02127354 0.01822702 
hsa05167 Kaposi's sarcoma-associated herpesvirus infection 30/660 186/7383 0.00099822 0.02146182 0.01838834 
hsa05216 Thyroid cancer 10/660 37/7383 0.00114164 0.02290891 0.0196282 
hsa04064 NF-kappa B signaling pathway 18/660 95/7383 0.00164551 0.0309561 0.02652297 
hsa04015 Rap1 signaling pathway 31/660 206/7383 0.00259247 0.04590195 0.03932848 
hsa05143 African trypanosomiasis 9/660 35/7383 0.00291415 0.04873102 0.04175241 
 
Table 7.4: KEGG analysis enriched pathways in hospitalised fatalities compared to survivors aged 5-45.  
ID Description GeneRatio BgRatio pvalue p.adjust qvalue 
hsa04610 Complement and coagulation cascades 16/75 79/7383 1.08E-11 2.49E-09 2.08E-09 
hsa04060 Cytokine-cytokine receptor interaction 11/75 270/7383 7.80E-05 0.00663011 0.00595273 
hsa05143 African trypanosomiasis 4/75 35/7383 0.00040521 0.01750511 0.01571666 
hsa05142 
Chagas disease (American 
trypanosomiasis) 6/75 102/7383 0.00055896 0.01750511 0.01571666 
hsa04668 TNF signalling pathway 7/75 108/7383 0.0006178 0.01221869 0.00989923 
hsa04620 Toll-like receptor signalling pathway 6/75 104/7383 0.00061988 0.01750511 0.01571666 
hsa04622 RIG-I-like receptor signalling pathway 5/75 70/7383 0.00068442 0.01750511 0.01571666 
hsa04659 Th17 cell differentiation 6/75 107/7383 0.0007208 0.01750511 0.01571666 
hsa05133 Pertussis 5/75 76/7383 0.00099657 0.02117709 0.01901349 
hsa05144 Malaria 4/75 49/7383 0.00147289 0.0278213 0.02497888 
hsa04064 NF-kappa B signaling pathway 7/75 95/7383 0.00174639 0.02124589 0.01721282 
Hsa04062 Chemokine signalling pathway 7/75 133/7383 0.00080803 0.02383708 0.02147675 





Table 7.5: KEGG analysis enriched pathways in hospitalised fatalities compared to survivors aged > 45 years. 
ID Description GeneRatio BgRatio pvalue p.adjust qvalue 
hsa04610 
Complement and coagulation 
cascades 13/149 79/7383 4.58E-09 1.08E-06 9.73E-07 
hsa05205 Proteoglycans in cancer 16/149 201/7383 2.53E-06 0.0002988 0.00026921 
hsa05150 Staphylococcus aureus infection 7/149 56/7383 0.00011997 0.00943738 0.0085029 
hsa04010 MAPK signalling pathway 16/149 295/7383 0.00028057 0.0165535 0.01491439 
hsa05202 
Transcriptional misregulation in 
cancer 12/149 186/7383 0.00035812 0.01690324 0.0152295 
hsa04979 Cholesterol metabolism 6/149 50/7383 0.00046672 0.01835782 0.01654006 
hsa04014 Ras signalling pathway 13/149 232/7383 0.00078736 0.02383708 0.02147676 
hsa04060 
Cytokine-cytokine receptor 




Table 7.6: KEGG analysis enriched pathways in hospitalised fatalities compared to survivors aged < 5 years. 
ID Description GeneRatio BgRatio pvalue p.adjust qvalue 
hsa05322 
Systemic lupus 
erythematosus 3/5 133/7383 5.57E-05 0.00027835 5.86E-05 
hsa05144 Malaria 3/5 180/7383 0.00013749 0.00034372 7.24E-05 
hsa04217 Necroptosis 2/5 164/7383 0.00469303 0.00636714 0.00134045 




7.3 PCR Profiler Array: Human Inflammatory Cytokines and 
Receptors (Qiagen) 
 
Table 7.7: Gene table RT2 Profiler PCR Array: Human Inflammatory Cytokines and 
Receptors. 96-well position shown for 84 target genes shown along with 
housekeeping genes and controls.  
 
 
 
 
 
 
 
 
